

Urinary markers in heart failure – types, timing and thresholds. *European Journal of Heart Failure* expert consensus document

Masatake Kobayashi^{1*}, Biykem Bozkurt², Peder Langeland Myhre^{3,4,5}, Juan Carlos Lopez Azor^{6,7}, Mateusz Guzik⁸, Gracjan Iwanek⁸, Guillaume Baudry⁹, Marta Cobo-Marcos^{6,7}, Òscar Miró¹⁰, Jeroen Dauw¹¹, Piotr Ponikowski⁸, Wilfried Mullens^{12,13}, Alberto Palazzuoli¹⁴, Marco Metra¹⁵, and Jan Biegus^{8*}

¹Department of Cardiology, Tokyo medical university, Tokyo, Japan; ²Cardiology Section, Winters Center for Heart Failure, Baylor College of Medicine, Houston, TX, USA; ³Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; ⁴Department of Cardiology, Akershus University Hospital, Lørenskog, Norway; ⁵Institute of Clinical Medicine, University of Oslo, Oslo, Norway; ⁶Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Majadahonda, Madrid, Spain; ⁷Departamento de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain; ⁸Department of Cardiology, Clinical Department of Intensive Cardiac Care, Wrocław Medical University, Faculty of Medicine, Institute of Heart Diseases, Wrocław, Poland; ⁹Université de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France; ¹⁰Emergency Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain; ¹¹Cardiovascular Center Aalst, AZORG Hospital, Aalst, Belgium; ¹²Department of Cardiology, Ziekenhuis Oost-Limburg A.V., Genk, Belgium; ¹³Hasselt University, Faculty of Medicine and Life Sciences, Diepenbeek, Belgium; ¹⁴Cardiovascular Diseases Unit, Cardio-Thoracic and Vascular Department, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy; and ¹⁵Cardiology, ASST Spedali Civili, and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy


Received 1 July 2025; revised 26 September 2025; accepted 6 October 2025; online publish-ahead-of-print 3 November 2025

Several urinary markers reflect disease severity and have the potential to support the management of heart failure (HF). Collecting urine samples is easy and inexpensive, and urine sample composition can be altered not only by underlying kidney impairments (i.e. filtration barrier damage and tubular injury) but also via neurohormonal and inflammatory activation, ageing, comorbidities, other medical conditions and pharmacological interventions. For instance, urinary sodium may help to predict the response to loop diuretic therapy in acute HF, while albuminuria is used as a risk marker and therapeutic target for the progression of cardiovascular and kidney diseases in chronic HF, especially when accompanied by kidney disease. However, these markers remain underutilized in clinical practice. This review paper underscores the role of urinary markers in HF, with a specific focus on: (i) the pathophysiologic mechanisms underlying urinary marker excretion, (ii) the prognostic values of urinary markers across diverse HF phenotypes and non-cardiovascular comorbidities (i.e. chronic kidney disease and diabetes), (iii) the impact of medical therapies on urinary markers, and (iv) existing knowledge gaps that challenge their implementation in clinical practice. The recommendations are aligned with current guidelines, evidence, and expert consensus.

.....

*Corresponding authors. Masatake Kobayashi, Department of Cardiology, Tokyo Medical University Hospital, Address: 6-7-1, Nishi-shinjuku, Shinjuku, Tokyo. Email: mkoba12@tokyo-med.ac.jp, mkoba12@me.com
Jan Biegus, Institute of Heart Diseases, Wrocław Medical University, 50-556 Wrocław, Borowska 213, Poland. Tel: +48-71-733 11 12. Email: jan.biegus@umw.edu.pl

Graphical Abstract



Pathophysiologic mechanisms of heart failure (HF) (i.e. renin–angiotensin–aldosterone system [RAAS], congestion, and inflammation), together with patient-related factors such as diabetes, hypertension, and chronic kidney disease (CKD), contribute to kidney function decline and glomerular or tubular injury. These alterations can be assessed through simple urinary marker tests. In acute HF, spot urinary sodium (UNa⁺) and urine volume provide important information on diuretic response, while in chronic HF, urinary albumin-to-creatinine ratio (UACR) reflects glomerular damage and is strongly associated with congestion as well as long-term CKD and/or cardiovascular disease (CVD) outcomes. Several guideline-directed therapies, including renin–angiotensin system inhibitors (RASi), mineralocorticoid receptor antagonists (MRA), sodium–glucose co-transporter 2 inhibitors (SGLT2i), and glucagon-like peptide-1 receptor agonists (GLP-1RA), support decongestion strategies by enhancing natriuresis with some agents and by reducing albuminuria. Incorporating urinary markers into routine clinical practice may therefore help improve patient care across the spectrum of HF. IV, intravenous; SNS, sympathetic nervous system.

Keywords

Heart failure • Urinary markers • Chronic kidney disease • Diabetes • Prognosis

Introduction

Heart failure (HF) is a growing global health burden, driven by increasing rates of comorbidities such as hypertension and diabetes.^{1,2} Chronic kidney disease (CKD), as part of a single entity with HF,^{3–5} further contributes to development and progression of HF.^{6–8} Once HF develops, the risks of hospitalization, mortality, and potential years of life lost are substantial, comparable to those faced by patients with cancer.⁹ Therefore, improved management encompassing the entire spectrum of HF, from prevention to treatment and monitoring, is urgently needed.

Obtaining urine samples is easy and inexpensive, and urine samples may reflect the status of kidney and cardiovascular (CV) system function.^{10,11} Urine volume is often monitored in patients hospitalized for acute HF to assess diuretic efficacy, while urinary markers are less frequently measured. With growing focus on kidney outcomes, incorporating urinary markers into routine care may help to improve patient care.^{12,13} Furthermore, reliance solely on temporary changes in estimated glomerular filtration rate (eGFR) may misguide the assessment of kidney injury or function, especially after initiating renin–angiotensin–aldosterone system (RAAS) inhibitors, mineralocorticoid receptor antagonists (MRAs)

or sodium–glucose co-transporter 2 (SGLT2) inhibitors.^{14,15} A better understanding of the appropriate types, timing, and thresholds of urinary markers may help improve the lifetime management of HF.¹⁶

This paper from the Cardio-Renal Disease Committee of the Heart Failure Association of the European Society of Cardiology (ESC) outlines the impact of urinary markers on cardiorenal outcomes, their interaction with HF therapies, and their clinical relevance across all HF stages to support clinical use.

Current guideline recommendations for urinary markers

The 2021 ESC guidelines define ‘diuretic response’ for the management of diuretic therapy in acute HF: spot urinary sodium concentration >50–70 mEq/L within 2 h and/or urinary output >100–150 ml/h during the first 6 h after diuretic infusion.¹⁷ The 2022 American Heart Association/American College of Cardiology (AHA/ACC) guidelines does not emphasize monitoring of urinary markers as objective metrics to guide diuretic therapy, but recommend the measure of urinalysis when patients are initially diagnosed with HF.¹⁸

Albuminuria has been traditionally assessed by dipstick, while urinary albumin-to-creatinine ratio (UACR) is a quantitative spot measure that adjusts for urine concentration and correlates well with 24-h excretion, especially in a morning sample.¹⁹ UACR is used to define CKD in combination with eGFR (UACR ≥ 30 mg/g or eGFR < 60 ml/min/1.73 m²). Multiple guidelines recommend UACR and eGFR for CKD screening, especially in people with hypertension or diabetes. Once CKD is diagnosed, these should be checked at least annually, or more often if CKD progression risk is high. The 2021 ESC prevention guidelines advise albuminuria assessment in men aged > 40 years and women aged > 50 years or postmenopausal.²⁰ The 2018 ESC/European Society of Hypertension guidelines recommend UACR screening for all patients with hypertension.²¹ The 2025 American Diabetes Association guidelines call for UACR and eGFR checks in type 1 diabetes ≥ 5 year duration and all type 2 diabetes (T2D), with 1–4 assessments per year if CKD is present.²² Similarly, the 2024 Kidney Disease: Improving Global Outcomes guidelines recommend monitoring UACR and eGFR at least annually in CKD, with more often in patients at higher risk of CKD progression.²³

Role of urinary biomarkers in heart failure

This document focuses on clinically useful markers and does not address those used mainly for research purposes. Various urinary biomarkers are utilized to evaluate the HF status, monitor renal and CV function, and therapeutic response.²⁴ Different biomarkers offer unique clinical insights; therefore, the combination of multiple markers and the trajectory of a single marker over time can yield more comprehensive clinical information than one value at a single time point.

It is essential to consider several general caveats when evaluating urinary biomarkers and their roles. First, the clinical meaning of a single biomarker can vary in relation to the population being assessed, for example, the stage of HF (A/B vs. C) and the patient's clinical status (acute HF vs. chronic HF). Moreover, some markers such as urinary sodium (UNa⁺) need to be assessed under specific (or at least known) conditions to have accurate interpretation and clinical relevance. It is also important to distinguish two major types of biomarkers that reflect two distinct mechanisms: dysfunction versus injury of a specific part of the nephron. As different urinary biomarkers have varying underlying pathophysiology and result from dysfunction or injury of different parts of the nephron, they convey distinct clinical meanings (Table 1). Injury biomarkers typically indicate irreversible damage to specific nephron cells or segments, being linked to cellular injury and apoptosis, similar to the role of troponin in heart injury assessment. The example of a kidney injury biomarker is neutrophil gelatinase-associated lipocalin (NGAL); however, clinical usefulness of these biomarkers in HF is still limited. In contrast, biomarkers that reflect renal dysfunction (usually as a response to the pathophysiological signals in HF) have much greater clinical relevance, and include both: markers of glomerular (e.g. eGFR, cystatin C) and tubular (like UNa⁺) dysfunction. As glomerular and tubular function is distinct, changes in eGFR do not necessarily reflect intrinsic tubular injury,

particularly in the context of acute HF following decongestive therapy.²⁵ Lastly, it should be also noted that the role of urinary biomarkers is significantly limited in patients with oliguria or anuria, where assessment of kidney function is critically important.

Diuresis and natriuresis associated markers

Urinary sodium concentration

Urinary sodium and chloride excretion reflect tubular ion handling and the degree of sodium avidity (the inner force to conserve and retain sodium). Key pathophysiological factors that control sodium excretion include blood pressure and renal perfusion, haemodynamics (especially central venous pressure), inflammation, neurohormonal activity, and fluid/sodium status.^{26–32} In HF, chronic exposure to diuretics additionally leads to structural and functional remodelling of the nephron, as reflected by a decreased natriuretic response to a given diuretic dose.^{33,34}

Generally, UNa⁺ refers to urinary sodium concentration measured in a urine sample, while natriuresis is defined as the total amount of sodium excreted at a given period. Most scientific evidence on the use of UNa⁺ comes from acute HF population particularly in the emergency settings, with limited data in chronic HF and pre-HF. Natriuresis, assessed by spot UNa⁺, is a key measure of diuretic response in acute HF and can be used to guide diuretic therapy,^{35,36} as recommended in the latest ESC guidelines,¹⁷ especially during the first 24 h. However, the use of UNa⁺ in clinical practice remains limited,³⁷ possibly due to a lack of awareness or logistical issues. The cutoff values to identify adequate diuretic response have been arbitrarily proposed to be UNa⁺ > 70 mmol/L after 2 h.³⁸ A low post-diuretic UNa⁺ may reflect persistent activation of sodium-retaining pathways and indicate the need for intensified diuretic therapy in most cases; thus, a cutoff value above 70 mmol/L may be appropriate.^{39,40} In the Pragmatic Urinary Sodium-based algorithm in Acute Heart Failure (PUSH-HF) trial, which included 310 patients with acute HF, a UNa⁺-guided algorithm led to greater increases in diuresis and natriuresis, without impacting hospitalization stay, 180-day HF rehospitalization nor all-cause mortality.⁴⁰ In the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT-HF) trial, which included 401 patients with acute HF, UNa⁺-guided therapy increased natriuresis, diuresis and shortened hospital stay.⁴¹ It is also noted that the relationship between UNa⁺ and urine volume is exponential (not linear), with higher UNa⁺ levels associated with relatively greater urine volume.⁴² Additionally, to some extent, UNa⁺ is independent of eGFR since they reflect different pathophysiological processes.⁴³ To enhance clinical applicability, UNa⁺ adjusted for urine dilution (based on urine creatinine) is proposed as a better predictor of diuretic response than unadjusted UNa⁺,⁴⁴ and spot UNa⁺-used formula may predict total urine and sodium output.⁴⁵

The second key role of UNa⁺ is to identify patients at high risk for HF-related events regardless of different HF severity or care setting (hospitalized or ambulatory).^{30,31,36,43,46–55} The natriuretic response to loop diuretics is interpreted as sodium avidity and, consequently, may reflect disease severity associated with

Table 1 Associations of urinary markers with outcomes in heart failure

Study/First author, Year	Population	LVEF, %	eGFR, ml/min/1.73 m ²	Follow-up period	Abnormal value of urinary marker	Outcomes associated with abnormal value of urinary marker
Natriuresis and natriuresis-associated urinary markers						
Singh, 2014 ⁴⁶	52 patients with acute HF	28 ± 15	55 ± 31	5 months	After initial IV furosemide, UNa ⁺ furosemide ratio <2 mmol/mg	Higher risk of WRF (adjusted OR 3.01, 95% CI 1.15–10.22; <i>p</i> = 0.02). Higher risk of mortality, HF hospitalization or cardiac transplantation (adjusted HR 1.62, 95% CI 1.13–2.39; <i>p</i> = 0.008). *main covariates: age, renal function, etc.
Ferreira, 2016 ⁴⁷	100 patients with acute HF	41 ± 12	53 ± 17	180 days	At day 3, UNa ⁺ > 100 mmol/L	Lower risk of CV death or HF hospitalization (HR 0.16, 95% CI 0.06–0.42; <i>p</i> < 0.01).
Doering, 2017 ⁴⁸	187 patients with acute HF	53% with LVEF <45%	53 (32–72)	30 days	After IV furosemide within 24 h of the ED visits, UNa ⁺ <50 mmol/L	Higher risk of HF rehospitalization.
Brinkley, 2018 ⁴⁹	176 patients with advanced HF in an ambulatory clinic	40 (25–55)	46 (33–57)	30 days	After IV furosemide bolus, UNa ⁺ <65 mmol/L and urine volume <1200 ml	UNa ⁺ <65 mmol/L/urine volume <1200 ml was associated with a ~4-fold higher 30-day hospitalization risk vs. UNa ⁺ ≥65 mmol/L/urine volume ≥1200 ml.
Luk, 2018 ⁵⁰	103 patients with acute HF	≈27	≈41	90 days	After an initial IV diuretic, UNa ⁺ ≤60 mmol/L	Higher risk of death, mechanical support, or inotrope use at discharge (HR 2.39, 95% CI 1.01–5.62; <i>p</i> = 0.047) after adjusting for baseline renal function.
Honda, 2018 ⁵¹	669 patients with acute HF	38 ± 17	39 ± 19	≈560 days	Immediately after hospitalization, UNa ⁺ ≤74 mmol/L	More frequent in-hospital WRF, and higher risk of death or worsening HF.
Collins, 2019 ⁵¹	61 patients with acute HF	50 (30–55)	48 (31–60)	In-hospital events	1 h after an initial IV diuretic, UNa ⁺ <35.4 mmol	Higher risk of worsening of HF events (100% sensitivity and 60% specificity).
Biegus, 2019 ³⁶	111 patients with acute HF	32 ± 13	63 ± 27	1 year	NA	Low spot UNa ⁺ and decrease/no change in UNa ⁺ in the 6 and 48 h samples were associated with higher risk of 1-year mortality.
Biegus, 2021 ⁴³	219 patients with acute HF	37 ± 14	58 ± 21	1 year	At day 1, UNa ⁺ <60 mmol/L	Higher risk of mortality or mortality/HF hospitalization.
Biegus, 2021 ³⁰	172 patients with acute HF	37 ± 14	Cr, 1.3 ± 0.5 mg/dl	1 year	NA	Higher UNa ⁺ after initial IV furosemide at admission, day 1 and day 2 (first morning urine samples) were associated with lower risk of mortality or HF hospitalization, while discharge UNa ⁺ was not.
Damman, 2020 ⁵⁴	175 patients with acute HF	35 ± 16	53 ± 26	257 days	6 h after first intravenous diuretic, UNa ⁺ <89 mmol/L	Higher risk of mortality (HR 6.24, 95% CI 1.94–20.0, <i>p</i> = 0.001) and HF hospitalization (HR 3.62, 95% CI 1.38–9.49, <i>p</i> = 0.009). Main covariates, urinary volume.
Elias, 2021 ⁵³	283 patients with chronic HF	76% with LVEF <40%	Cr, 1.3 ± 0.4 mg/dl	5 years	Morning UNa ⁺ <80 mmol/L and furosemide ≥80 mg/day	Higher risk of mortality.
Caravaca, 2021 ⁵²	65 patients with acute HF who underwent furosemide stress test, IV furosemide bolus within the first 24 h after admission	40 ± 16	66 ± 21	6 months	At 2 h after the furosemide stress test, UNa ⁺ <113 mmol/L	A smaller reduction in NT-proBNP, longer hospital stay, a higher risk of in-hospital worsening HF, and death/HF rehospitalization over 6 months.
Nawrocka-Millward, 2024 ⁶²	248 patients with acute HF	37 ± 14	Cr at 24 h, 1.3 ± 0.5 mg/dl	1 year	Admission UCI <115 mmol/L	Higher risk of combined in-hospital mortality, inotropic support, worsening HF, need for intensive cardiac care unit, and adverse CV outcomes over 1 year.
Cobo-Marcos M, 2025 ⁵⁵	167 patients with ambulatory worsening HF	50 ± 15	40 (29–53)	30 days	Three hours after IV diuretics, UNa ⁺ <107 mmol/L	Higher 30-day risk of death, HF hospitalization, and outpatient IV diuretic use.
Meekers, 2025 ⁵⁹	50 patients with stable HF	46 ± 11	47 (35–65)	NA	NA	Patients with successful diuretic down-titration showed increased first-void UNa ⁺ (<i>p</i> < 0.001), unlike those needing re-initiation (<i>p</i> = 0.33). A 10 mmol/L UNa ⁺ increase predicted this success (AUC = 0.85; sensitivity 79.4%, specificity 78.6%).

Table 1 (Continued)

Study/First author, Year	Population	LVEF, %	eGFR, ml/min/1.73 m ²	Follow-up period	Micro-, and macro-albuminuria	HF-related outcomes associated with albuminuria ^a
Albuminuria, urinary albumin-to-creatinine ratio HOPE, 2001 ⁸⁸	Individuals with a history of CV disease (n = 5545) or diabetes and at least one CV risk factor (n = 3498)	NA	NA	4.5 years	Micro-albuminuria (UACR ≥2 mg/mmol): 32.6% in diabetes and 14.8% in non-diabetes Macro-, 100%	Outcome: HF hospitalization Micro-albuminuria; HR 3.08 (95% CI 2.49–3.82) *Each 0.4 mg/mmol increase in UACR increased the risk of HF hospitalization by 11%. UACR ≥3 g/g vs. <1.5 g/g: higher risk of HF onset (=2.70, 95% CI 1.94–3.75) *Each 50% reduction in albuminuria was associated with 18% lower risk of CV events and with 27% lower risk of HF onset.
RENAAL, 2004 ⁸³	1513 patients with T2D and CKD	NA	40 ± 12	3.4 years	NA	Outcome: developing HF Micro-albuminuria; HR 2.73, 95% CI 1.56–4.78 Macro-albuminuria; HR 5.27, 95% CI 2.30–12.11 Main covariates: established CV risk factors
MESA, 2008 ⁸¹	6814 participants	NA	NA	4 years	NA	Outcome: developing HF Micro-albuminuria; HR 2.49, 95% CI 1.77–3.50 Macro-albuminuria; HR 3.47, 95% CI 2.10–5.72 Main covariates: renal function and CV risk factors
ARIC Study, 2011 ⁸²	10 975 individuals free from HF	NA	NA	8.3 years	Micro-, 6.2% Macro-, 1.3%	Higher albuminuria levels were associated with a higher risk of developing HFpEF, but not HFpEF.
PREVEND, 2013 ⁸²	8592 individuals from a community-based, middle-aged cohort	NA	81 ± 15	11.5 years	NA	Outcome: developing HFpEF Higher UACR; HR 1.33, 95% CI 1.20–1.48
CHS, FHS, MESA, PREVEND, 2018 ⁸⁰	22 756 participants in 4 longitudinal community-based cohorts	NA	NA	12 years	NA	Outcome: developing HFpEF Higher UACR; HR 1.21, 95% CI 1.11–1.32
SPRINT substudy, 2021 ⁸⁶	8913 individuals at high risk for or with CV disease, a systolic blood pressure of 130–180 mmHg but without diabetes	NA	28.4% with eGFR <60	3.2 years	Micro-, 16.3% Macro-, 2.8%	Outcome: hospitalization or emergency department visit for HF Higher risk increased stepwise from normo- to micro- to macro-albuminuria, regardless of eGFR above or below 60 ml/min/1.73 m ² .
FIDELITY (FIGARO-DKD/ FIDELIO-DKD), 2022 ⁸⁷	13 026 patients with T2D and CKD (UACR 30–5000 mg/g and eGFR ≥25 ml/min/1.73 m ²)	NA	58 ± 22	3 years	Micro-, 31.5% Macro-, 66.7%	Outcome: first hospitalization for HF Higher risk increased stepwise from normo- to micro- to macro-albuminuria, regardless of eGFR above or below 60 ml/min/1.73 m ² .
SOLVD, 2000 ¹²⁴	5487 patients with HF and LVEF ≤35%	26 ± 6	NA	41.4 months	3.2%, proteinuria by dipstick	Outcome: HF hospitalization Proteinuria; HR 1.81, 95% CI 1.37–2.41 Outcome: mortality
CHARM program, 2009 ⁹²	2310 patients with chronic HF	39 ± 16	76 ± 30	37.7 months	Micro-, 30% Macro-, 11%	Proteinuria; HR 1.73, 95% CI 1.34–2.24. Outcome: CV mortality or HF hospitalization Micro-albuminuria; HR 1.50, 95% CI 1.28–1.75 Macro-albuminuria; HR 1.88, 95% CI 1.53–2.33 Main covariates: treatment allocation (candesartan vs. placebo), diabetes, hypertension and NYHA class.
GISSI-HF, 2010 ⁹¹	2131 patients with chronic HF	33 ± 9	Cr. 1.2 ± 0.4	2.9 years	Micro-, 20% Macro-, 5%	Outcome: mortality Micro-albuminuria; HR 1.42, 95% CI 1.11–1.81 Macro-albuminuria; HR 1.70, 95% CI 1.16–2.50 Main covariates: diabetes, hypertension and renal function.

Table 1 (Continued)

Study/First author, Year	Population	LVEF, %	eGFR, ml/min/1.73 m ²	Follow-up period	Micro- and macro-albuminuria	HF-related outcomes associated with albuminuria ^a
CHART-2, 2012 ⁹⁴	2465 patients with HF and LVEF ≥50% in Japan	65 ± 9	62 ± 24	2.5 years	29.5%, proteinuria by dipstick	Outcome: CV death Higher risk with proteinuria, regardless of eGFR above or below 60 ml/min/1.73 m ² .
Katz, 2014 ⁹⁶	144 patients with ambulatory HF and LVEF ≥50%	62 ± 7	58 ± 23	12.1 months	Micro-, 25% Macro-, 14%	Main covariates: diabetes and CV diseases Every UACR doubling was associated with greater RV remodelling (0.9 mm wall thickening, worse systolic function) and higher risk of CV mortality or hospitalization (HR 1.13, 95% CI 1.05–1.31).
TOPCAT, 2018 ⁹³	1175 patients with HF and LVEF ≥45% from TOPCAT Americas	58 ± 8	65 ± 21	3.5 years	Micro-, 35% Macro-, 13%	Outcome: CV mortality, aborted cardiac arrest, or HF hospitalization Micro-albuminuria: HR 1.47, 95% CI 1.15–1.86 Macro-albuminuria: HR 1.67, 95% CI 1.22–2.28 Covariates: diabetes, renal function and NYHA class *Each UACR reduction by 50% was associated with 10% lower risk of HF hospitalization and 9% lower risk of mortality.
Shuvy, 2020 ⁹⁵	4668 patients with HF in Israel	NA	68 (48–90)	2 years	Micro-, 38% Macro-, 17%	Outcome: mortality Micro-albuminuria: HR 1.18, 95% CI 1.02–1.38 Macro-albuminuria: HR 1.33, 95% CI 1.10–1.61
Matsumoto, 2022 ¹⁰¹	140 patients hospitalized for acute HF	43 ± 18	52 ± 25	1 years	Micro-, 59% Macro-, 23% *Admission UACR	Main covariates: diabetes, hypertension and renal function. Outcome: HF rehospitalization Higher risk increased stepwise from normo- to micro- to macro-albuminuria collected at admission.
BIOSTAT-CHF, 2023 ¹⁰²	2315 patients with worsening HF (LVEF ≤40% or BNP >400 pg/ml or NT-proBNP >2000 pg/ml)	31 ± 11	51 ± 15	21 months	Micro-, 35.4% Macro-, 10.0%	Outcome: CV death or HF hospitalization Higher risk increased stepwise from normo- to micro- to macro-albuminuria, regardless of HFpEF or HFpEF
Ioannou, 2024 ¹⁰³	1181 patients with ATTR-CA	48 ± 10	59 (47–74)	≤60 months	Micro-, 88.6% Macro-, 11.4%	Outcome: mortality Micro-albuminuria: HR 1.47, 95% CI 1.13–1.92 Macro-albuminuria: HR 1.87, 95% CI 1.15–3.05 Main covariates: diabetes and National Amyloidosis Centre disease stage *Among 330 patients without hypertension/diabetes or CKD, ≥30% UACR increase was associated with higher risk of 1-year mortality (HR 1.84, 95% CI 1.06–3.19; p = 0.030).

ATTR-CA, transthyretin cardiac amyloidosis; AUC, area under the curve; BNP, B-type natriuretic peptide; CI, confidence interval; CKD, chronic kidney disease; Cr, creatinine; CV, cardiovascular; ED, emergency department; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, heart failure and preserved ejection fraction; HFREF, heart failure and reduced ejection fraction; HR, hazard ratio; IV, intravenous; LVEF, left ventricular ejection fraction; NA, not available; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OR, odds ratio; T2D, type 2 diabetes; UACR, urinary albumin-to-creatinine ratio; UCI, urinary chloride; UNa⁺, urinary sodium; WRF, worsening renal function.
^aHazard ratios for HF-related events are presented for micro- and macro-albuminuria, compared to normo-albuminuria.

adverse outcomes.³² Thus, low UNa^+ in response to diuretics is associated with poor outcomes (i.e. in-hospital complications, HF rehospitalization, and death).^{31,36,43,56} Patients who fail to increase urine sodium with diuretics and require escalating diuretic dose are at high risk of outcomes.³⁹ Furthermore, a simple assessment of UNa^+ in acute HF provides insight into intrinsic renal sodium avidity and may help predict decongestive effectiveness, regardless of diuretic use.⁵⁷ In patients with ambulatory HF, serial UNa^+ assessments showed that declines in UNa^+ preceded HF hospitalization, while increases in UNa^+ predicted successful diuretic down-titration, potentially aiding the management of ambulatory patients with HF.^{58,59}

Urinary chloride

Urinary chloride (UCI^-) is tightly linked to UNa^+ , serving as a key factor of tubuloglomerular feedback regulation, modulating renin and aldosterone activity.⁶⁰ In patients hospitalized for acute HF, lower UCI^- levels on admission were significantly associated with higher blood-based markers of RAAS (i.e. plasma renin activity and serum aldosterone)⁶¹ as well as with the risk of worsening renal function (WRF) and post-discharge adverse events.^{62,63} During decongestion therapy, trajectories of UCI^- levels were strongly correlated with changes in UNa^+ at all time points from admission to hour 6. The UCI^- trajectory was influenced by the chronic use of diuretics and may serve as a predictor of diuretic response, similar to observations with UNa^+ .⁶⁴

Fractional excretion of sodium

Fractional excretion of sodium (FeNa) is a calculated variable that describes how efficiently the kidneys reabsorb/excrete sodium. It is believed that FeNa reflects the renal tubular function in response to haemodynamic, hormonal, and metabolic stimuli.^{65,66} From a clinical perspective, FeNa has primarily been used for the diagnosis of acute tubular necrosis and its aetiology. A FeNa $<1\%$ suggests prerenal azotaemia and sodium retention (i.e. dehydration, renal artery stenosis, and HF). However, the use of diuretics will increase sodium excretion (by design), often pushing FeNa above 1%, even if the underlying physiology is prerenal, which significantly limits the interpretation of this biomarker in the context of acute tubular necrosis.

Fractional excretion of urea

Another measure that is derived from both urine and serum biomarkers to assess kidney function in HF, is fractional excretion of urea (FeUrea). The advantage of FeUrea is that it remains a more reliable measure of tubular function even when diuretics have been used. FeUrea serves as a surrogate for renal blood flow and tubular integrity: low FeUrea suggests effective volume depletion or low flow to the kidney, whereas high FeUrea implies intrinsic dysfunction or perhaps an overhydrated state where urea retention signals are minimal. FeUrea $<35\%$ had a 98% positive predictive value for prerenal azotaemia, significantly outperforming FeNa in this context.⁶⁵ Potentially, FeUrea in HF serves two roles:

(1) diagnostic work-up of acute renal dysfunction (prerenal vs. intrinsic), especially useful when loop diuretics confound FeNa, and (2) as an index of volume status and perfusion that can help optimize congestion status during decongestion.^{67,68} Notably, the interpretation of FeNa/FeUrea values should always be performed within the clinical context, rather than in isolation (Table 2).

Urine volume

Urine volume is a simple and clinically meaningful marker of kidney function in HF. In the acute setting, low urine volume despite adequate diuretic therapy – commonly referred to as diuretic resistance – may signal poor renal perfusion, neurohormonal activation, and progressive cardiorenal syndrome. Reduced urine volume (<100 ml/h or <500 ml/24 h) is associated with persistent fluid overload, increased central venous pressure, and a higher risk of in-hospital mortality and rehospitalization.^{38,69} Conversely, an adequate or brisk diuretic response, reflected by early and sustained natriuresis and increased urine volume, is a favourable prognostic marker, indicating effective decongestion and preserved renal tubular function. Therefore, monitoring urine volume over time can aid in therapeutic decision-making and risk stratification in both acute HF and chronic HF.

Monitoring urine volume in HF is simple, non-invasive, and provides real-time feedback on the effectiveness of decongestive therapy, making it a valuable and cost-effective bedside tool. Measuring urine volume in the hour after a diuretic bolus can help identify patients with diuretic resistance and stratify potential HF risk, particularly in the acute setting. However, urine volume captures only changes in total body water, while the upstream cause of congestion is sodium accumulation rather than water retention.^{70,71} Thus, it is a non-specific marker of decongestion, and its accuracy can be affected by diuretic timing and the absence of catheterization.

Albuminuria

Albuminuria is a marker of compromised glomerular integrity, permeability, and endothelial dysfunction. Increased central venous pressure, renal venous congestion and increased intraglomerular pressure allow albumin to leak into the urine, while neurohormonal activation (i.e. aldosterone) promotes kidney fibrosis and disrupts the glomerular filtration barrier.^{72,73} Thus, an elevated UACR in HF often reflects early renal injury from a combination of volume overload, RAAS overactivation, comorbidities (i.e. diabetes, hypertension and CKD), and microvascular inflammation.^{72,74,75}

Clinical practice guidelines classify UACR levels as moderately increased (micro-albuminuria: 30–300 mg/g or 3–29 mg/mmol) and severely increased (macro-albuminuria: ≥ 300 mg/g or ≥ 30 mg/mmol).⁷⁶ Even with normal eGFR, the presence of macro-albuminuria is recognized as an at high-risk population and a therapeutic target for slowing kidney disease progression in the latest guidelines. The associations between UACR levels and CV and kidney disease risk were well-documented even at levels below the micro-albuminuria threshold.^{77–79} These associations also align with a risk of HF development. Greater albuminuria

Table 2 The proposed interpretation of fractional excretion of sodium and of urea

Optimal thresholds for FeNa and FeUrea	Interpretation
FeNa <1% or FeUrea <35%	A prerenal cause of AKI, such as hypovolaemia, dehydration, or HF.
FeNa 1–2% or FeUrea 35–50%	An indeterminate range.
FeNa >2% or FeUrea >50%	An intrinsic renal cause of AKI (e.g. acute tubular necrosis, toxic nephropathy)

AKI, acute kidney injury; FeNa, fractional excretion of sodium; FeUrea, fractional excretion of urea; HF, heart failure.

excretion is associated with a higher risk of developing HF in the communities.^{80–82} In high-risk individuals (i.e. diabetes and/or CKD), the presence of micro-albuminuria is associated with a ~2–3-fold increased risk of developing HF.^{83–87} Among individuals with CV disease or risk factors, even slight increases in UACR significantly heightened the risk of HF progression; each 0.4 mg/mmol rise in UACR was associated with 11% higher HF hospitalization risk.⁸⁸ Furthermore, incorporating albuminuria into HF risk models enhances the accuracy of 10-year risk prediction in individuals who were free of HF.^{89,90}

For patients with chronic HF, the risk of HF-related outcomes (e.g. CV death or HF hospitalization) consistently increases stepwise from normo-albuminuria to micro-albuminuria and further to macro-albuminuria, regardless of patients with HF and a reduced ejection fraction (HFrEF) and a preserved ejection fraction (HFpEF).^{91–96} Furthermore, the association between albuminuria reduction and HF-related event risk reduction was also reported.^{83,93} In a sub-analysis of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOP-CAT) trial, each UACR reduction by 50% was associated with 10% lower risk of HF hospitalization and 9% lower risk of mortality in HFpEF.⁹³

Preclinical and clinical studies suggest that albuminuria is considered as a marker of congestion,^{97,98} which may reflect the high prevalence of micro-albuminuria in acute HF (~70%) compared to chronic HF (~40%).^{93,96,99–101} In a cohort study of 115 patients with acute HF, UACR significantly decreased from admission to day 7, paralleling decreases in circulating natriuretic peptide levels.¹⁰⁰ In 2315 patients with worsening HF from European countries, higher UACR levels were associated with markers of congestion, including clinical signs, echocardiographic findings, key biomarkers (i.e. natriuretic peptide, cancer antigen 125, adrenomedullin), as well as with worse prognosis.¹⁰² Similar associations with disease severity and prognosis were also observed in transthyretin cardiac amyloidosis.¹⁰³

Effects of guideline-directed therapies on diuretic/natriuretic markers and albuminuria

Certain foundational therapies for HF, CKD or T2D improve kidney health, i.e. increase natriuresis and reduce albuminuria and eGFR decline in the long term. RAAS inhibitors may improve diuretic efficacy,¹⁰⁴ while SGLT2 inhibitors add glucosuria-driven diuresis.^{105,106} In the STRONG-HF trial, rapid in-hospital initiation

or up-titration of HF therapies improved post-discharge prognosis,¹⁰⁷ which was linked with more effective decongestion, compared to usual care.¹⁰⁸

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEIs/ARBs), SGLT2 inhibitors, and finerenone have reduced albuminuria in CKD, especially in patients with T2D, with most of the reduction observed within 4 weeks of initiation.^{109–115} A 30% reduction in UACR over a 6-month period has been suggested as a surrogate marker for a 30% reduction in the risk of CKD and CV disease progression.^{116,117} Although some uncertainties remain, albuminuria is expected to serve as a surrogate for HF progression.⁷⁴ Importantly, RAAS inhibitors, MRAs and SGLT2 inhibitors caused an early decrease in eGFR without kidney injury or loss of clinical benefits. This favourable effect is mirrored by a sustained albuminuria reduction, which may reflect better treatment response than eGFR alone. Key results supporting the effects of HF therapies on urinary markers are presented in Table 3.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

Among patients at risk of HF, ACEIs/ARBs increased natriuresis and reduced albuminuria.^{118,119} In patients with diabetes and hypertension who have micro- or macro-albuminuria or eGFR <60 ml/min/1.73 m², ACEI/ARB use is recommended.²² Established evidence showed that, among patients with diabetes, ACEIs/ARBs reduced UACR levels, particularly in those with macro-albuminuria, and prevented the development of micro-albuminuria,^{114,120,121} while albumin reduction lowered a risk of developing HF.^{83,122} However, albuminuria-lowering effects of ACEIs/ARBs in HF are limited by comorbidities such as diabetes.^{92,123–125}

Angiotensin receptor–neprilysin inhibitors

Angiotensin receptor–neprilysin inhibitors (ARNI) may also enhance natriuresis. In a sub-analysis of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, which included 8399 patients with HFrEF (81% on diuretics at baseline), ARNI was associated with more frequent diuretic dose reductions and fewer dose increases compared with enalapril over 1 year.¹²⁶ The NATriuretic Response to expansion and diUretics in huMans

Table 3 The effects of heart failure foundational therapies on urinary markers and clinical outcomes

Study/First author, Year	Population	HF stage	Trial design	Intervention	Follow-up for urinary markers	Urinary marker outcomes	Clinical outcomes
Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers							
RENAAL, 2001 ¹¹⁴	1513 patients with CKD and type 2 diabetes (Cr ≈ 1.9 mg/dl, UACR ≈ 1250 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Losartan 50–100 mg/day vs. placebo	3.4 years	Losartan reduced UACR by 35%, while placebo increased it ($p < 0.001$ for the overall treatment effect). Trandolapril decreased the incidence of micro-albuminuria, regardless of verapamil use.	Doubling serum creatinine, ESKD, or death: 16% risk reduction. First hospitalization for HF: 32% risk reduction.
BENEDICT, 2004 ¹²¹	1204 patients with type 2 diabetes and hypertension, but with normo-albuminuria (Cr ≈ 0.9 mg/dl, UACR ≈ 5 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Trandolapril plus verapamil vs. trandolapril alone vs. verapamil alone vs. placebo	3.6 years		
ROADMAP, 2011 ¹²⁰	4447 patients with type 2 diabetes (eGFR ≈ 85, UACR ≈ 4 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Olmesartan 40 mg/day vs. Placebo	3.2 years	Micro-albuminuria development: 23% risk reduction (95% CI 6–37%).	
SOLVD, 2000 ^{124,125}	5310 patients with chronic HF and absence of baseline proteinuria (LVEF ≈ 27%)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Enalapril vs. placebo	2 years	Proteinuria: 62% reduction in 970 patients with diabetes but not in 4335 without diabetes.	Mortality: 16% risk reduction (95% CI 5–26%).
CHARM, 2009 ^{92,123}	2310 North American patients with chronic HF (LVEF ≈ 39%, eGFR ≈ 75)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Candesartan vs. placebo	14 months	Albuminuria: no reduction.	Mortality: no reduction over a median follow-up of 37.7 months (HR 0.90, 95% CI 0.83–1.00, $p = 0.055$).
Angiotensin receptor–neprilysin inhibitors, sacubitril/valsartan							
NATRIUM-HF, 2024 ¹²⁷	216 patients with chronic HF and LVEF < 40% (LVEF ≈ 34%, NT-proBNP ≈ 210 pg/ml)	Stage C, chronic HF	Non-randomized, pre-post intervention study	Before and at 2 and 3 months after sacubitril/valsartan initiation, patients underwent 3 phases: (i) rest (0 to 3 h), (ii) load (3 to 6 h, 1 L IV Ringer solution), and (iii) diuretic (6 to 9 h, furosemide given at start)	At month 3	At month 3, sacubitril/valsartan-treated patients showed greater natriuresis than at baseline and greater diuresis during the load phase at months 2 and 3. Natriuresis increased significantly more than in sacubitril/valsartan-naïve patients, without a rise in urine volume.	
UK HARP-III, 2018 ¹³¹	414 patients with CKD (eGFR ≈ 35, UACR ≈ 54 mg/g, diabetes 40%)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Sacubitril/valsartan 400 mg/day vs. irbesartan 300 mg/day	12 months	UACR: no difference.	
PARAMOUNT, 2015 ^{134,135}	301 patients with chronic HF and LVEF ≥ 45% (LVEF ≈ 58%, eGFR ≈ 65, UACR ≈ 15 mg/g, NT-proBNP ≈ 850 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Sacubitril/valsartan 400 mg/day vs. valsartan 320 mg/day	36 weeks	UACR increased in the sacubitril/valsartan group, whereas it remained stable in the valsartan group (p between groups = 0.016).	NT-proBNP: 23% reduction at 12 weeks (95% CI 8–36%).

Table 3 (Continued)

Study/First author, Year	Population	HF stage	Trial design	Intervention	Follow-up for urinary markers	Urinary marker outcomes	Clinical outcomes
PARADIGM-HF, 2018 ^{132,133}	1872 patients with chronic HF and LVEF ≤40% (LVEF ≈30%, eGFR ≈67, UACR ≈9 mg/g, NT-proBNP ≈110 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Sacubitril/valsartan 400 mg/day vs. enalapril 20 mg/day	8 months	>25% increase in UACR was more common in the sacubitril/valsartan group vs. the enalapril group ($p < 0.01$).	CV death or HF hospitalization: 20% risk reduction (95% CI 13–27%) after a median follow-up of 27 months.
PARALLAX, 2021 ¹³⁶	2572 patients with chronic HF and LVEF >40% (LVEF ≈56%, eGFR ≈63, UACR ≈15 mg/g, NT-proBNP ≈770 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Sacubitril/valsartan vs. active control (i.e. enalapril and valsartan) or placebo stratified by prior use of a renin-angiotensin system inhibitor	24 weeks	Albuminuria was more often in patients treated with sacubitril/valsartan.	NT-proBNP: 16% reduction at 12 weeks (95% CI 12–20%).
Beta-blockers							
Bakris, 2005 ¹⁴⁰	1210 patients with hypertension and type 2 diabetes	Stage A/B	Double-blind, randomized, parallel-group trial	Metoprolol tartrate vs. carvedilol	5 months	16% reduction in micro-albuminuria with carvedilol (95% CI 6–25%). Among those with normo-albuminuria, fewer developed micro-albuminuria on carvedilol vs. metoprolol ($p = 0.03$), independent of blood pressure changes.	
Mineralocorticoid receptor antagonists							
Ferreira, 2014 ¹⁴¹	100 patients with acute HF (LVEF ≈43%, Cr ≈1.1 mg/dl, NT-proBNP ≈2900 pg/ml)	Stage C, acute HF	Open-label, non-randomized trial with sequential 1:1 allocation	Spirolactone 50–100 mg/d vs. control	3 days	UNa ⁺ : increase.	NT-proBNP: reduction at day 3.
ATHENA-HF, 2017 ¹⁴³	360 hospitalized patients with acute HF (LVEF ≈33%, Cr ≈1.2 mg/dl, NT-proBNP ≈4100 pg/ml)	Stage C, acute HF	Double-blind and placebo (or low-dose)-controlled randomized clinical trial	High-dose spironolactone (100 mg) vs. placebo or 25 mg spironolactone (usual care) daily	96 h	Urine volume: no difference.	NT-proBNP: no reduction. Body weight: no change. Congestion relief: no difference. Diuretic dose change: no difference.
MIRAD, 2021 ¹⁴⁸	140 patients with CKD and type 2 diabetes (eGFR ≈85, UACR ≈17 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Eplerenone 100–200 mg/day vs. placebo	26 weeks	UACR: 34% reduction (95% CI 12–51%)	Risk of 30-day mortality or HF hospitalization: no difference.
Oiwa, 2023 ¹⁴⁷	130 patients with CKD and type 2 diabetes (eGFR ≈65, 60% with UACR ≥30 mg/g)	Stage A/B	Open-label randomized trial	Spirolactone 12.5 mg/day vs. Control	24 weeks	UACR: reduction	
ARTS-DN, 2015 ¹⁵⁰	823 patients with CKD and type 2 diabetes (40% with eGFR ≤60, 37% with UACR ≥300 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Finerenone (1.25, 2.5, 5, 7.5, 10, 15 and 25 mg/day) vs. placebo	90 days	UACR reduction (vs. placebo): 21% with 7.5 mg/day, 24% with 10 mg/day, 33% with 15 mg/day, and 38% with 20 mg/day of finerenone.	
FIDELIO-DKD, 2020 ¹⁰⁹	5734 patients with CKD and type 2 diabetes (eGFR ≈44, UACR ≈850 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Finerenone 10–20 mg/day vs. placebo	2.6 years	UACR: 31% reduction from baseline to month 4 and sustained thereafter.	Kidney composite outcomes: 18% risk reduction (95% CI 7–27%)

Table 3 (Continued)

Study/First author, Year	Population	HF stage	Trial design	Intervention	Follow-up for urinary markers	Urinary marker outcomes	Clinical outcomes
FIGARO-DKD, 2021 ¹¹⁰	7437 patients with CKD and type 2 diabetes (eGFR \approx 68, UACR \approx 310 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Finerenone 10–20 mg/day vs. placebo	3.4 years	UACR: 32% reduction from baseline to month 4 and sustained thereafter. UACR: 29% reduction (finerenone/empagliflozin vs. finerenone) vs. 32% reduction (finerenone/empagliflozin vs. empagliflozin).	CV composite outcomes: 13% risk reduction (95% CI 2–24%) Blood pressure: doubled with combination (finerenone/empagliflozin) vs. alone.
CONFIDENCE, 2025 ¹³⁶	800 patients with CKD and type 2 diabetes (eGFR \approx 54, UACR \approx 580 mg/g)	Stage A/B	Double-blind, randomized trial	Finerenone 10–20 mg/day + empagliflozin 10 mg/day vs. finerenone 10–20 mg/day vs. empagliflozin 10 mg/day	180 days	UACR: 29% reduction (finerenone/empagliflozin vs. finerenone) vs. 32% reduction (finerenone/empagliflozin vs. empagliflozin).	Blood pressure: doubled with combination (finerenone/empagliflozin) vs. alone.
ARTS-HF, 2013 ¹³²	392 patients with HF+EF and moderate CKD (LVEF \leq 40%, eGFR \approx 47, UACR \approx 20 mg/g, NT-proBNP \approx 1400 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial and open-label spironolactone comparator arms	Finerenone (2.5, 5, or 10 mg q.d., or 5 mg twice daily) was compared with placebo and open-label spironolactone (25 or 50 mg/day)	1 month	UACR: reduction in all finerenone dose groups and in spironolactone group, whereas increase in placebo group.	NT-proBNP: reduction in all finerenone dose groups and in spironolactone group, whereas a small increase in placebo group.
TOPCAT Americas, 2018 ^{93,135}	1175 patients with chronic HF and LVEF \geq 45% (LVEF \approx 58%, eGFR \approx 65, 50% with UACR \geq 30 mg/g, NT-proBNP \approx 900 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Spironolactone 25–50 mg/day vs. control	1 year	UACR: 39% reduction in overall patients and 76% reduction among those with macro-albuminuria.	CV death, aborted cardiac arrest or HF hospitalization: 18% risk reduction over a median follow-up of 3.3 years in TOPCAT Americas (95% CI 2–31%).
FINEARTS-HF, 2025 ^{133,154}	5797 patients with chronic HF and LVEF \geq 40% (LVEF \approx 52%, 50% with eGFR \geq 60, 50% with UACR \approx 60 mg/g, NT-proBNP \approx 1100 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Finerenone 40 mg/day vs. placebo	2.6 years	UACR: 30% reduction from baseline to month 6 and sustained thereafter. New-onset of micro-albuminuria: 24% reduction. New-onset of macro-albuminuria: 38% reduction.	CV death, first or recurrent HF hospitalization or urgent visit for HF: 16% risk reduction over a median follow-up of 32 months (95% CI 5–26%)
Sodium–glucose co-transporter 2 inhibitors Mordi, 2020 ¹⁶⁸	23 patients with diabetes and stable HF (70% with LVEF $<$ 45%, 75% with eGFR \geq 60, NT-proBNP \approx 2400 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled crossover trial	Empagliflozin 25 mg/day vs. placebo	6 weeks with a 2-week washout period	Urine volume: increase on day 3 and after 6 weeks. Fractional sodium or 24-h urinary sodium excretion: no increase.	NT-proBNP: no change. Body weight: decrease at week 6.
Griffin, 2020 ¹⁵⁸	20 patients with diabetes and HF (LVEF \approx 43%, eGFR \approx 70, NT-proBNP \approx 400 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled crossover trial	Empagliflozin 10 mg/day vs. Placebo	Each for 14 days	Urine volume: increase. Fractional and total sodium excretion: increase. Urinary KIM-1: decrease.	NT-proBNP: no change. Body weight: decrease. Blood volume: decrease. Plasma volume: decrease.

Table 3 (Continued)

Study/First author, Year	Population	HF stage	Trial design	Intervention	Follow-up for urinary markers	Urinary marker outcomes	Clinical outcomes
EMPA-RESPONSE-AHF, 2020 ¹⁶³	79 patients with ADHF (LVEF \approx 36%, eGFR \approx 55, NT-proBNP \approx 5200 pg/ml)	Stage C, acute HF	Double-blind, randomized, placebo-controlled trial	Empagliflozin 10 mg/day vs. Placebo	30 days	Urine volume: increase. Fractional sodium or 24-h urinary sodium excretion: no change.	Dyspnoea score: no change. Diuretic response: no change. Length of hospital stay: no change.
Tamaki, 2021 ¹⁶⁶	59 patients with type 2 diabetes, within 96 h of ADHF (LVEF \approx 44%, eGFR \approx 38, NT-proBNP \approx 3200 pg/ml)	Stage C, acute HF	Open-label randomized trial	Empagliflozin 10 mg/day vs. other diabetic therapy	7 days	Urine volume: increase. 24-h urinary sodium excretion: increase.	Body weight: no change. NT-proBNP on day 4: no change.
EMPAG-HF, 2022 ¹⁶⁴	60 patients with ADHF, within 12 h of admission (LVEF \approx 45%, eGFR \approx 38, NT-proBNP \approx 3200 pg/ml)	Stage C, acute HF	Double-blind, randomized, placebo-controlled trial	Empagliflozin 25 mg/day vs. placebo	5 days	Urine volume: increase. Fractional sodium excretion or total urinary sodium excretion: no change.	Body weight: no change. NT-proBNP: reduction.
Kolwelter, 2023 ¹⁶⁹	74 patients with stable HF (LVEF \approx 40%, eGFR \approx 74, NT-proBNP \approx 450 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo controlled parallel-group trial	Empagliflozin 10 mg/day vs. placebo	3 months	Urine volume: increase. 24-h urinary sodium excretion: no change.	Body weight: decrease. NT-proBNP: no change.
DAPA-RESIST, 2023 ¹⁶⁷	61 hospitalized patients with fluid retention resistant to loop diuretics (LVEF \approx 40%, eGFR \approx 41, NT-proBNP \approx 4000 pg/ml)	Stage C, acute HF	Open-label, randomized, parallel group trial	Dapagliflozin 10 mg/day vs. metolazone 5–10 mg daily	3 days	Urine volume: no change. UNa^+ : increase.	Cumulative furosemide dose: decrease.
DICTATE-AHF, 2024 ¹⁶⁵	240 patients with hypervolaemic acute HF within 24 h of hospital presentation (LVEF \approx 40%, eGFR \approx 53, NT-proBNP \approx 2600 pg/ml)	Stage C, acute HF	Open-label, randomized, parallel group trial	Dapagliflozin 10 mg/day vs. control	5 days	Urine volume: increase. 24-h urinary sodium excretion: increase.	Body weight: no change. Pulmonary congestion (lung ultrasound): no change. Fluid volume: no change. Cumulative weight change/cumulative loop diuretic dose: no change.
EMPA-REG OUTCOME, 2017 ⁷⁸	4304 patients with type 2 diabetes and at high CV risk (eGFR \approx 74, 40% with $UACR \geq 30$ mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Empagliflozin 10 or 25 mg/day vs. placebo	164 weeks	UACR: 29% reduction (95% CI 110–44%) in macro-albuminuria. 22% reduction (95% CI 11–32%) in micro-albuminuria. 1% reduction (95% CI –10% to 8%) in normo-albuminuria. Progression to macro-albuminuria: 38% reduction.	CV death, non-fatal MI, or non-fatal stroke: 14% reduction (95% CI 1–26%). HF hospitalization: 35% reduction (95% CI 15–50%).

Table 3 (Continued)

Study/First author, Year	Population	HF stage	Trial design	Intervention	Follow-up for urinary markers	Urinary marker outcomes	Clinical outcomes
CREDESCENCE, 2019 ¹¹¹	4401 patients with CKD and type 2 diabetes (eGFR \approx 56, UACR \approx 927 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Canagliflozin 100 mg/day vs. placebo	2.62 years	UACR: 31% reduction (95% CI 26–35%)	ESKD, serum creatinine doubling or renal/CV death: 30% reduction (95% CI 18–41%). HF hospitalization: 39% reduction (95% CI 20–53%). ESKD, eGFR decline >50% or renal/CV death: 39% reduction (95% CI 28–49%). CV death or HF hospitalization: 29% reduction (95% CI 8–45%).
DAPA-CKD, 2020 ¹¹²	4304 patients with CKD (eGFR \approx 43, UACR \approx 950 mg/g, diabetes 68%)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Dapagliflozin 10 mg/day vs. Placebo	2.0 years	UACR: 29% reduction (95% CI 26–35%). UACR reduction was greater in T2D than non-diabetes (<i>p</i> for interaction <0.001).	ESKD, eGFR decline >50% or renal/CV death: 39% reduction (95% CI 28–49%). CV death or HF hospitalization: 29% reduction (95% CI 8–45%).
EMPA-KIDNEY, 2023 ¹¹³	6609 patients with CKD (eGFR \approx 37, UACR \approx 330 mg/g, diabetes 46%)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Empagliflozin 10 mg/day vs. placebo	2.0 years	UACR: 19% reduction (95% CI 15–23%).	CKD progression or CV death: 28% reduction (95% CI 18–36%).
EMPEROR-program (EMPEROR-Reduced and Preserved), 2022 ^{180–182}	9673 patients with stable HF (LVEF \approx 44%, eGFR \approx 58, UACR \approx 110 mg/g, NT-proBNP \approx 1310 pg/ml)	Stage C, chronic HF	Patient level meta-analysis of double-blind, randomized, placebo-controlled trial	Empagliflozin 10 mg/day vs. placebo	EMPEROR-Reduced, 16 months EMPEROR-Preserved, 26.2 months	New macro-albuminuria: 19% reduction (95% CI 6–30%). Remission to sustained normo- or micro-albuminuria: 31% increase (95% CI 7–59%). UACR: 19% reduction in diabetes, 12% reduction in macro-albuminuria no change in overall population.	CV death or HF hospitalization EMPEROR-Reduced: 25% reduction (95% CI 24–35%). EMPEROR-Preserved: 21% reduction (95% CI 10–31%).
Glucagon-like peptide-1 receptor agonists LEADER, 2016 ¹⁸⁵	9340 patients with high CV risk and type 2 diabetes (BMI \approx 33 kg/m ² , 24% with eGFR \leq 60, 12% with UACR \geq 30 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Liraglutide 1.8 mg/day vs. placebo	3.8 years	In a pooled analysis of LEADER and SUSTAIN-6 UACR reduction (vs. placebo): 24% (20–27%) from baseline to year 2.	CV death, non-fatal MI and non-fatal stroke: HR 0.87, 95% CI 0.78–0.97.
SUSTAIN-6, 2016 ¹⁸⁶	3297 patients with type 2 diabetes (BMI \approx 33 kg/m ² , 70% with eGFR \leq 60)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Semaglutide 0.5 or 1.0 mg/week vs. placebo	2.1 years	UACR reduction (vs. placebo): 10.7% (9.2%–13.2%) from baseline to week 104.	CV death, non-fatal MI and non-fatal stroke: HR 0.74, 95% CI 0.58–0.95.
SELECT, 2023 ^{187,188}	17 604 obese patients without diabetes (BMI \approx 33 kg/m ² , 11% with eGFR <60, 14% with UACR \geq 30 mg/g)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Semaglutide 2.4 mg/week vs. placebo	40 months		CV death, non-fatal MI and non-fatal stroke: HR 0.80, 95% CI 0.72–0.90.

Table 3 (Continued)

Study/First author, Year	Population	HF stage	Trial design	Intervention	Follow-up for urinary markers	Urinary marker outcomes	Clinical outcomes
FLOW, 2024 ¹⁸⁹	3533 patients with CKD and type 2 diabetes (BMI \approx 32 kg/m ² , eGFR \approx 47, UACR \approx 570)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Semaglutide 1.0 mg/week vs. placebo	3.4 years	UACR reduction (vs. placebo): 32% (25–38%) from baseline to week 104.	ESKD: >50% decrease in eGFR or kidney/CV-related death: HR 0.76, 95% CI 0.66–0.88). CV death or worsening HF event: HR 0.62, 95% CI 0.41–0.95.
SUMMIT, 2025 ^{192,193}	731 patients with HFpEF and obesity (BMI \approx 38 kg/m ² , LVEF \approx 60%, eGFR \approx 64, NT-proBNP \approx 200 pg/ml)	Stage C, chronic HF	Double-blind, randomized, placebo-controlled trial	Tirzepatide up to 15 mg/week vs. placebo	104 weeks	UACR reduction (vs. placebo): 25% (13–36%) from baseline to week 24, 15% (–0.1% to 28%) from baseline to week 52.	
Diuretics DOSE, 2011 ¹⁹⁵	308 patients with ADHF (LVEF \approx 35%, Cr \approx 1.5 mg/dl, NT-proBNP \approx 7400 pg/ml)	Stage C, acute HF	Double-blind, randomized and controlled trial	Either a low-dose or high-dose strategy and to administration of furosemide either by IV bolus every 12 h or by continuous IV infusion	72 h	Urine volume: Greater in high-dose vs. low-dose strategy No change between continuous and bolus infusion groups.	Symptomatic congestion: greater relief in high-dose vs. low-dose strategy. Body weight: greater reduction in high-dose vs. low-dose strategy NT-proBNP: greater reduction in high-dose vs. low-dose strategy WRF: more often in high-dose vs. low-dose strategy
CLOROTIC, 2023 ¹⁹⁷	230 patients with ADHF who required furosemide 80–240 mg/day (LVEF \approx 56%, eGFR \approx 43, NT-proBNP \approx 4500 pg/ml)	Stage C, acute HF	Double-blind, randomized, placebo-controlled trial	Hydrochlorothiazide vs. placebo	5 days	24 h urine volume: 27% increase. 96 h natriuresis: increase.	72 h body weight: reduction. Patient-reported dyspnoea: no difference.
DIURESIS-CHF, 2019 ²⁰²	34 patients with acute HF at high risk for loop diuretic resistance (LVEF \approx 43%, eGFR \approx 31, NT-proBNP \approx 7850 pg/ml)	Stage C, acute HF	Single-blind, randomized and controlled trial	Acetazolamide 250–500 mg/day and low-dose loop diuretics vs. monotherapy with high-dose loop diuretics	72 h	24 h natriuresis: no difference. 24-h natriuresis corrected for loop diuretic dose: increase.	WRF (>0.3 mg/dl Cr): increase. 72-h NT-proBNP: no reduction. Peak neurohumoral activation: no change. Mortality or HF hospitalization: no difference.
ADVOR, 2023 ^{39,203}	462 patients with ADHF (LVEF \approx 43%, eGFR \approx 48, NT-proBNP \approx 6000 pg/ml)	Stage C, acute HF	Double-blind, randomized, placebo-controlled trial	Acetazolamide vs. placebo	72 h	UNa ⁺ : increase. Total natriuresis: increase.	Successful decongestion (no signs of volume overload by day 3 without therapy escalation): 46% increase (95% CI 17–82%). Catheter-assessed intracardiac pressure (i.e. pulmonary capillary wedge pressure): decrease.
ECLIPSE, 2008 ²⁰⁶	181 patients with advanced HF (LVEF \approx 24%, Cr <3.0 mg/dl)	Stage C/D, chronic HF	Double-blind, randomized, placebo-controlled trial	Tolvaptan at a single oral dose (15, 30 or 60 mg) vs. placebo	12 h	Urine volume: increase. Urinary osmolality: decrease.	

Table 3 (Continued)

Study/First author, Year	Population	HF stage	Trial design	Intervention	Follow-up for urinary markers	Urinary marker outcomes	Clinical outcomes
TACTICS-HF, 2017 ²⁰⁵	257 patients with ADHF (LVEF \approx 33%, Cr \approx 1.5 mg/dl, NT-proBNP \approx 10 200 pg/ml)	Stage C, acute HF	Double-blind, randomized, placebo-controlled trial	Tolvaptan 30 mg vs. placebo	72 h	48-h fluid loss: increase. 72-h fluid loss: no difference.	Dyspnoea relief at 8 h: no change. Dyspnoea relief at 24 h: no change. Need for rescue therapy: no change. In-hospital outcomes: no change. Post-discharge outcomes: no change. Body weight: decrease. WRF: more often.
CLICK, 2021 ²⁰¹	160 patients with stage 4 CKD and uncontrolled hypertension (eGFR \approx 23, UACR \approx 840 mg/g, NT-proBNP \approx 590 pg/ml, diabetes 75.6%)	Stage A/B	Double-blind, randomized, placebo-controlled trial	Chlorthalidone vs. placebo	12 weeks	UACR: 50% reduction (95% CI 37–60%).	24 h systolic blood pressure: 10.5 mmHg reduction.
Vasodilators							
ASCEND-HF, 2013 ^{207,208}	4881 patients with ADHF (LVEF \approx 30%, eGFR \approx 60, NT-proBNP \approx 4500 pg/ml)	Stage C, acute HF	Double-blind, randomized, placebo-controlled trial	Nesiritide vs. placebo	24 h	24-h urine volume: no difference.	Dyspnoea at 6 h: improved. Dyspnoea at 24 h: improved. Death or HF rehospitalization: no difference. WRF: no difference. Symptom relief: no difference. NT-proBNP: no change. WRF: no difference. Hypotension: no difference.
ROSE, 2013 ²⁰⁹	360 patients with acute HF and renal dysfunction (eGFR 15–60 ml/min/1.73 m ²) (LVEF \approx 33%, eGFR \approx 43, NT-proBNP \approx 5100 pg/ml)	Stage C, acute HF	Double-blind, randomized, placebo-controlled trial	Patients were first randomized 1:1 to dopamine or nesiritide groups. Within each, they were further randomized in a double-blind 2:1 ratio to low-dose dopamine or placebo, and low-dose nesiritide or placebo, respectively	72 h	72-h cumulative urine volume: no difference.	
LASCAR-AHF, 2025 ²¹⁰	247 patients with ADHF (LVEF \approx 30%, eGFR \approx 60, NT-proBNP \approx 4500 pg/ml)	Stage C, acute HF	Open-label, randomized controlled trial	Carperitide vs. control	72 h	72-h cumulative urine volume: no difference.	Death or HF hospitalization at 2 years: no difference. Dyspnoea: no difference. BNP: no reduction.

ADHF, acute decompensated heart failure; BNP, B-type natriuretic peptide; CI, confidence interval; CKD, chronic kidney disease; Cr, creatinine; CV, cardiovascular; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; HF, heart failure; HR, hazard ratio; KIM-1, kidney injury molecule-1; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; UACR, urinary albumin-to-creatinine ratio; UNa⁺, urinary sodium; WRF, worsening renal function.

with Heart Failure (NATRIUM-HF) trial showed increased UNa^+ and urine volume at 2–3 months after ARNI initiation compared to baseline.¹²⁷ The natriuretic and diuretic effect of ARNI may mirror its clinical benefits in worsening HF, regardless of left ventricular ejection fraction (LVEF).^{128–130}

The effect of ARNI on albuminuria excretion may differ between HF and non-HF populations. In the United Kingdom Heart and Renal Protection-III (UK HARP-III) trial, which included 414 patients with CKD (eGFR 20–60 ml/min/1.73 m²), ARNI did not alter UACR levels over 12 months compared with irbesartan.¹³¹ In contrast, among trials with available albuminuria data, ARNI consistently increased UACR levels in patients with HF, compared with comparators, including enalapril in HFREF from the PARADIGM-HF trial, valsartan in HFpEF from the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejection fracTion (PARAMOUNT) trial, and control (i.e. enalapril, valsartan, or placebo) in HFpEF from the Prospective Comparison of ARNI vs Comorbidity-Associated Conventional Therapy on Quality of Life and Exercise Capacity (PARALLAX) trial, despite robust CV benefits, particularly in HFREF, and potential renal risk reduction.^{132–138} These intriguing findings may reflect ARNI-induced afferent vasorelaxation and efferent vasoconstriction, which together increase intracapillary hydraulic pressure and albumin ultrafiltration, partly via natriuretic peptides.¹³⁹

Beta-blockers

The impact of beta-blockers on urinary markers has been scarcely reported. In patients with diabetes, their effects on blood pressure, sympathetic tone, and vascular inflammation may influence podocyte integrity and endothelial function, potentially altering albuminuria.¹⁴⁰

Mineralocorticoid receptor antagonists

Although preclinical studies support the natriuretic effects of MRAs, clinical data in HF remain limited.^{141,142} In the Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF) trial, which included 360 patients with acute HF, spironolactone 100 mg/day did not increase urine volume, reduce natriuretic peptides, nor improve congestion over 72 h in acute HF, compared to placebo or spironolactone 25 mg/day.¹⁴³ However, given the slow onset of spironolactone (>24 h), eplerenone, with its shorter half-life and faster onset, may be more suitable for acute HF.⁴ In the Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER) trial, which included 300 patients with acute HF, eplerenone versus placebo reduced diuretic requirements, lowered natriuretic peptide, and improved echocardiographic measures of cardiac filling pressures despite lacking urinary data.^{144,145}

Mineralocorticoid receptor antagonists, both steroidal and non-steroidal, consistently reduced albuminuria in patients with CKD.^{146–150} In particular, finerenone lowered UACR levels compared with placebo in 5734 patients with T2D and advanced CKD in the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial,¹⁰⁹

and also in 7437 patients with a broader eGFR range (up to 90 ml/min/1.73 m²) and moderate albuminuria (≈ 310 mg/g) in the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial.¹¹⁰ Using these data, 30% UACR reduction with finerenone was associated with a lower risk of kidney outcomes by 64% and CV outcomes by 26%.¹⁵¹ Similarly, steroidal or non-steroidal MRAs reduced albuminuria in HF. In the MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF) trial, spironolactone or finerenone lowered UACR levels over 1 month in patients with HFREF and CKD.¹⁵² In the TOPCAT Americas and Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trials, spironolactone and finerenone reduced UACR levels compared with placebo, findings that may align with their potential benefits in HFpEF and HF with mildly reduced ejection fraction.^{93,153–155} It should be noted that, in TOPCAT Americas, reducing UACR by 50% was independently associated with reduced risk of all-cause mortality and HF hospitalization.⁹³

Furthermore, a combination of finerenone and empagliflozin reduced UACR levels by approximately 30% greater than either drug alone in T2D and CKD.¹⁵⁶ Whether MRAs/SGLT2 inhibitors may further reduce albuminuria in HF and help prevent HF progression warrants further investigation.¹⁵⁷

Sodium–glucose co-transporter 2 inhibitors

Sodium–glucose co-transporter 2 inhibitors block glucose reabsorption and simultaneously modulate tubular sodium reabsorption through their structural coupling with sodium–hydrogen exchanger isoform (NHE3).¹⁵⁸ Given the varied pharmacokinetics of SGLT2 inhibitors across HF severity, evidence was conflicting on whether their natriuretic or glycosuric effects increased diuresis in acute HF.^{159–169} In the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF) and Empagliflozin in Acute Decompensated Heart Failure (EMPAG-HF) trials, empagliflozin 10 mg and 25 mg, respectively, increased urine volume over 4–5 days compared to placebo without affecting UNa^+ ,^{162–164} while another trial showed empagliflozin 10 mg/day versus control increased UNa^+ at 24 h.¹⁶⁶ However, despite the various natriuretic effects and the attenuated diuretic response observed over time,¹⁷⁰ the EMPagliflozin 10 mg compared with placebo, initiated in patients hospitalized for acUte heart failUre who have been StabilisEd (EMPULSE) trial showed that patients treated with empagliflozin experienced greater congestion relief and clinical benefit compared to those with placebo in acute HF.^{171,172} In-hospital initiation of SGLT2 inhibitor may reduce the early risk of CV death in patients with acute HF.¹⁷³

Sodium–glucose co-transporter inhibitors reduce albuminuria and slow progression from micro- to macro-albuminuria in patients with T2D and/or CKD,^{111,113,174–178} likely due to reduced intraglomerular hyperfiltration and tubular inflammation.¹⁷⁹ In the EMPAREG-OUTCOME trial, which included 4304 patients with T2D and high CV risk, empagliflozin reduced UACR

levels compared to placebo.¹⁷⁸ Albuminuria-lowering effects of SGLT2 inhibitors were also confirmed in landmark CKD trials: canagliflozin in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CRENCE; 4401 patients with T2D and CKD),¹¹¹ dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD; 4304 patients with CKD),¹¹² and empagliflozin in the Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY; 6609 patients with CKD).¹¹³ However, their effects on albuminuria reduction in HF remain insufficiently studied. In the EMPEROR-program, empagliflozin versus placebo consistently reduced the risk of HF-related events and new-onset macro-albuminuria, and increased remission to normo- or micro-albuminuria irrespective of LVEF, whereas UACR reduction was limited to patients with concomitant diabetes or baseline macro-albuminuria.^{180–182}

Glucagon-like peptide-1 receptor agonists

Glucagon-like peptide-1 (GLP1) receptor agonists reduced albuminuria particularly in patients with diabetes, by inhibiting renal oxidative stress, fibrosis and apoptosis.^{183,184} Among patients with coexisting diabetes and/or obesity, GLP1 receptor agonists are associated with significant UACR reductions compared to placebo, regardless of comorbid CKD.^{185–190} However, despite the potential albuminuria reduction effects in patients at risk of HF (i.e. diabetes, obesity and CKD), whether this drug reduced future HF events remained unclear, particularly in HFrEF.^{185,191} Nonetheless, among obese patients with HFpEF (LVEF >50%), in the SUMMIT trial, tirzepatide versus placebo reduced the risk of CV death or worsening HF events over 104 weeks, while lowering circulating natriuretic peptide levels, increasing eGFR, and decreasing UACR levels over 52 weeks.^{192,193}

Diuretic therapy, vasodilators, and extracorporeal ultrafiltration

Loop diuretics, which inhibit NaCl reabsorption in the ascending limb of the Henle loop, have steep dose–response curves, with minimal natriuretic effect below a threshold dose.⁶⁶ Their efficacy may be limited by enhancing distal NaCl reabsorption with chronic use, known as ‘braking phenomenon’³³ as well as gut oedema, hypoperfusion, and hypoalbuminaemia which reduce oral absorption and tubular binding.¹⁹⁴ In the Diuretic Optimization Strategies Evaluation (DOSE) trial, high-dose intravenous furosemide improved diuresis and symptom relief but increased the risk of WRF despite no overall efficacy difference among dose strategies or modes of administration (i.e. continuous infusion or bolus) in acute HF.¹⁹⁵

As other diuretic agents, thiazides block NaCl reabsorption in the distal tubule and increase natriuresis even in cases with loop diuretic resistance via ‘sequential nephron blockage’.¹⁹⁶ The classical perspective was recently supported by the results of the Combination of Loop With Thiazide-type Diuretics in Patients

With Decompensated Heart Failure (CLOROTIC) trial, in which adding hydrochlorothiazide versus placebo increased 24-h diuresis and natriuresis despite no impact on clinical outcomes in acute HF.¹⁹⁷ Thiazide or thiazide-like diuretics also reduce albuminuria excretion in CKD due to reduced intraglomerular pressure.^{198–201} Furthermore, acetazolamide, a carbonic anhydrase inhibitor, blocks proximal tubular sodium reabsorption. In the Diamox/Aldactone to Increase the Urinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure (DIURESIS-CHF) trial, acetazolamide plus bumetanide versus high-dose loop diuretics increased 24-h natriuresis corrected for loop diuretic dose.²⁰² In the Acetazolamide in Decompensated Heart Failure with Volume Overload (ADVOR) trial, acetazolamide versus placebo increased natriuresis (>30%), urine volume (>500 ml) over 2 days and achieved successful decongestion.^{39,203} Tolvaptan, a vasopressin-2 receptor antagonist, acts on collecting duct, inhibiting water reabsorption without altering UNa⁺. Tolvaptan substantially increased urine volume, weight loss, and had short-term favourable effects on the degrees of congestion in acute HF, despite their neutral effects on CV outcomes.^{204–206}

Vasodilators may stabilize haemodynamics and accelerate congestion relief in patients with acute HF; treatment with vasodilators failed to augment diuresis, natriuresis or diuretic efficacy.^{207–210}

Furthermore, after ultrafiltration, UNa⁺ generally decreases since ultrafiltration mechanically removes excess plasma volume and solutes (i.e. sodium), often extracting more sodium than diuretic interventions, which causes RAAS activation and enhances tubular sodium reabsorption.^{211,212} While ultrafiltration may achieve efficient decongestion and reduce the risk of rehospitalization, whether it reduces mortality risk remains uncertain.^{213–215}

Other urinary markers

Several other urinary markers were assessed for their diagnostic and prognostic values in patients with HF; however, they are not commonly measured in clinical practice. For example, urinary kidney injury molecule-1 (KIM-1) was approved for assessing drug-related toxic side effects in clinical trials, but not for routine clinical use.²¹⁶ Measuring urinary NGAL may incur excessive medical expenses, limited insurance coverage and inconsistent reimbursement across healthcare systems. Other urinary markers (i.e. NGAL, KIM-1, N-acetyl-β-D-glucosaminidase [NAG], β-2-microglobulin, N-terminal pro-B-type natriuretic peptide [NT-proBNP] and proteomics) are discussed in online supplementary material.

Urinary markers between heart failure with reduced and preserved ejection fraction

Given that distinct pathophysiology, risk factor profiles, and treatment responses of HFrEF and HFpEF,^{217,218} urinary biomarker compositions may differ between these two phenotypes. Patients with HFpEF are more likely to present with albuminuria and


Urine markers for HF clinical practice	Setting			Interpretation	HF therapy effects				
	At risk	Acute HF	Chronic HF		ACEi/ARB	ARNI	MRA	SGLT2i	GLP1 RA
									
Urine Na⁺ (Spot urinary Na ⁺)	—	✓	?	Key measure of natriuresis >50-70 mEq/L 2 hours after initial IV diuretic indicates good response	=	↑	=	↑	=
Urine volume	—	✓	—	Key measure of diuresis >600-900 mL 6 hours after initial IV diuretic indicates good response	=	=	=	↑	=
Albuminuria (UACR)	✓	✓	✓	A marker of congestion Predicts CV, renal and HF events. Prognostic value	↓	↑	↓	↓	↓

Figure 1 Practical guidance of urinary markers across heart failure (HF) stages. Across HF stages, urinary sodium (Na⁺), urine volume and albuminuria provide important clinical insights. Urinary Na⁺ and volume are particularly relevant in acute HF, as they help guide diuretic therapy and achieve adequate decongestion. Albuminuria is a surrogate marker for cardiovascular (CV) and HF risk stratification, especially in patients with diabetes and/or chronic kidney disease (CKD), and may also serve as a congestion marker in acute HF. Beyond diuretics, which increase both diuresis and natriuresis (except for vaptans), angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium–glucose co-transporter 2 inhibitors (SGLT2i) increase diuresis, whereas SGLT2i may also increase natriuresis. Most guideline-directed medical therapies lower albuminuria, with the exception of ARNIs, which modestly increase it despite their robust cardiorenal benefits. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; GLP1 RA, glucagon-like peptide-1 receptor agonist; IV, intravenous; MRA, mineralocorticoid receptor antagonists; UACR, urinary albumin-to-creatinine ratio.

show greater severity of albuminuria, compared to those with HFpEF.^{102,219} This finding is likely attributable to HFpEF-specific pathophysiology, including systemic endothelial dysfunction and microvascular rarefaction as well as relatively high prevalence of comorbidity burdens such as diabetes and CKD.^{220–222} Additionally, beyond glomerular leakage, intrinsic tubular injury or dysfunction may contribute more prominently to kidney impairment in HFpEF than in HFrfEF, as suggested by higher levels of tubular injury markers such as urinary NGAL, KIM-1, and NAG.^{75,219} However, it remains unclear whether these differences in urinary markers translate into distinct prognostic implications between HFpEF and HFrfEF, or whether they represent modifiable therapeutic targets.

Current challenging and practical approach

In clinical practice, natriuresis and albuminuria are not routinely measured. In a global survey on the management of acute HF, spot UNa⁺ was infrequently or never measured by ≥85% of physicians, although UNa⁺ and urine volume are more commonly measured in academic centres than in non-academic centres.³⁷ Albuminuria screening rates are globally suboptimal, even among individuals at risk of developing CKD and/or HF.^{223–225} To mitigate the existing knowledge gaps that challenge their implementation in clinical practice, we present a summary of clinical information on urinary biomarkers across different stages of HF (Figure 1).

At risk of heart failure

In patients with hypertension and diabetes, annual UACR measurement is recommended. If macro-albuminuria persists for ≥3 months or eGFR falls below 60 ml/min/1.73 m², a diagnosis of CKD is made. Treatment should include initiation of an ACEi/ARB and an SGLT2 inhibitor, and finerenone is also recommended in patients with T2D and CKD to mitigate potential risk of developing HF. UACR can be re-assessed at least 4 weeks after treatment initiation to identify responders to these treatments. Subsequently, UACR measurements can be monitored one to four times per year, depending on their risk of progression.

Stage C, acute heart failure

In patients hospitalized for acute HF with volume overload, UNa⁺ and urine volume should be measured 2 h after initiating intravenous diuretics; if UNa⁺ is <70 mmol/L or urine volume is <150 ml/h, the diuretic treatment should be intensified. When diuretic therapy should be optimized on the first day, and once an adequate response is achieved, the same dose should be repeated every 12 h until decongestion is achieved. If 24-h urine volume remains <3 L and congestion persists, further escalation of diuretic doses should be considered. Additional strategies include ultrafiltration, inotropes in cases with low-output states, or combination diuretic therapy (acetazolamide or oral thiazide) in cases with poor diuretic response.

Urinary albumin-to-creatinine ratio can be also monitored during HF hospitalization. During decongestion therapy, UACR typically decreases from admission to the compensated stage, reflecting renal decongestion.

Stage C, chronic heart failure

Patients with chronic HF should be treated with RAAS inhibitors and SGLT2 inhibitors, and steroidal MRAs (i.e. spironolactone and eplerenone) for HFrEF and finerenone for HFpEF. Alongside beta-blockers (for HFrEF), these therapies should be initiated and up-titrated within 6 weeks following acute HF hospitalization if tolerated. UACR should be rechecked 4 weeks after initiation, and can be also interpreted in the context of congestion status, optimized with HF treatments (e.g. diuretics), and closely monitored over time. Additionally, UNa⁺ is also monitored to identify patients with high risk of HF-related events.

Future directions

Dedicated trials for urinary markers are essential to implement into clinical practice. For UNa⁺ monitoring, several ongoing trials will further evaluate the usefulness of protocolized diuretic therapy in patients with acute HF. The Urine Chemistry Guided Acute Heart Failure Treatment (ESCALATE; NCT04481919) trial is focusing on diuretic titration until decongestion,²²⁶ whereas the Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment (DECONGEST; NCT05411991) trial is assessing combination therapy with acetazolamide and chlorthalidone, using a hierarchical composite outcome (i.e. mortality, morbidity and natriuretic peptide change).²²⁷ The use of point-of-care sensor for UNa⁺ may facilitate nurse-led diuretic titration or ambulatory diuretic down-titration, thereby enhancing clinical adoption.^{59,228} However, as examples of natriuretic peptide-guided management,^{229,230} whether natriuresis-guided therapy is weighed over usual care in terms of hard clinical outcomes remains unclear.⁴⁰ Furthermore, as albuminuria changes over 6 weeks are considered surrogate endpoints of CKD progression, within the framework of the heart–kidney continuum, it remains unclear whether direct reduction of albuminuria translates into improved HF outcomes, namely, successful decongestion in acute HF and reductions in worsening HF events and CV death in chronic HF.^{83,93} Other urinary markers (e.g. NGAL, KIM-1 and NAG) may help clarify the pathophysiology of HF and identify patient subgroups at heightened risk of adverse outcomes. Their clinical adoption, however, awaits robust validation across diverse populations, regulatory approval, and clear demonstration of cost-effectiveness.

Conclusions

Urinary markers, particularly natriuresis and albuminuria, show promise throughout the entire journey of HF from prevention to treatment and monitoring, with natriuresis being used for acute HF management and albuminuria benefiting both prevention and monitoring of chronic HF (especially comorbid CKD). Ongoing trials are

expected to clarify the clinical benefits of urinary markers, which may improve routine care for HF. Further evidence from clinical trials and real-world experience, based on guideline-directed management, could promote the broader adoption of these markers in clinical practice.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Conflict of interest: M.K. has received speaker fees from Boehringer Ingelheim, Eli-Lilly, Bayer, Daiichi-Sankyo, AstraZeneca, Novartis, and Ono, Kowa and Mochida pharmaceutical company. B.B. has received consultancy fees from Abbott, Abiomed, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva Nova, Merck, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi Aventis, and Vifor. P.L.M. has served on advisory boards and/or received speaker fees from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Novo Nordisk, Pharmacosmos, Roche, Sanofi, US2.ai, and Vifor. G.B. has received personal fees from Abbott, AstraZeneca, and Boehringer Ingelheim. J.D. has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, and Novartis and travel grants from AstraZeneca, Bayer and Daiichi Sankyo. P.P. has received consultancy fees on advisory boards, and received speaker honoraria from Boehringer Ingelheim, AstraZeneca, Vifor Pharma, Servier, Novartis, Merck, Moderna, Bayer, MSD, Abbott Vascular, Novo Nordisk, Pharmacosmos, Reprieve, WhiteSwell, and Relaxera. M.M. has received consulting honoraria from Bayer, Boehringer Ingelheim, Medtronic, Novo Nordisk, and Roche Diagnostics. J.B. has received honoraria from Bayer, Boehringer Ingelheim, and AstraZeneca for lectures, and from Alleviant Medical, Reprieve Cardiovascular, and WhiteSwell for participation in clinical trial advisory boards. All other authors have nothing to disclose.

References

- Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. *Eur J Heart Fail* 2020;**22**:1342–1356. <https://doi.org/10.1002/ehf.1858>
- Tsao CW, Aday AV, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke Statistics-2023 update: A report from the American Heart Association. *Circulation* 2023;**147**:e93–e621. <https://doi.org/10.1161/CIR.0000000000001123>
- Zoccali C, Mallamaci F, Halimi JM, Rossignol P, Serafidis P, De Caterina R, et al. Chronic cardiovascular-kidney disorder: A new conceptual framework. *Nat Rev Nephrol* 2024;**20**:201–e202. <https://doi.org/10.1038/s41581-023-00789-8>
- Kobayashi M, Giererd N, Zannad F. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases. *Nephrol Dial Transplant* 2024;**39**:1063–1072. <https://doi.org/10.1093/ndt/gfae004>
- Bozkurt B. Advances and challenges in holistic treatment of cardiometabolic kidney disease as one entity. *JACC Heart Fail* 2024;**12**:1949–1951. <https://doi.org/10.1016/j.jchf.2024.10.002>
- Halimi JM, de Fréminville JB, Gatault P, Bisson A, Gueguen J, Goin N, et al. Long-term impact of cardiorenal syndromes on major outcomes based on their chronology: A comprehensive French nationwide cohort study. *Nephrol Dial Transplant* 2022;**37**:2386–2397. <https://doi.org/10.1093/ndt/gfac153>
- Sharma A, Inzucchi SE, Testani JM, Ofstad AP, Fitchett D, Mattheus M, et al. Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease. *ESC Heart Fail* 2024;**11**:737–747. <https://doi.org/10.1002/ehf2.14601>
- Kobayashi M, Bayes-Genis A, Duarte K, McMurray JJV, Ferreira JP, Pocock SJ et al. Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction. *Eur Heart J* 2025;**46**:4583–4593. <https://doi.org/10.1093/eurheartj/ehaf457>

9. Stewart S, Ekman I, Ekman T, Odén A, Rosengren A. Population impact of heart failure and the most common forms of cancer: A study of 1 162 309 hospital cases in Sweden (1988 to 2004). *Circ Cardiovasc Qual Outcomes* 2010;**3**:573–580. <https://doi.org/10.1161/CIRCOUTCOMES.110.957571>
10. Njoku K, Chiasserini D, Jones ER, Barr CE, O'Flynn H, Whetton AD, et al. Urinary biomarkers and their potential for the non-invasive detection of endometrial cancer. *Front Oncol* 2020;**10**:559016. <https://doi.org/10.3389/fonc.2020.559016>
11. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, et al. Urine in clinical proteomics. *Mol Cell Proteomics* 2008;**7**:1850–1862. <https://doi.org/10.1074/mcp.R800001-MCP200>
12. Khan MS, Bakris GL, Packer M, Shahid I, Anker SD, Fonarow GC, et al. Kidney function assessment and endpoint ascertainment in clinical trials. *Eur Heart J* 2022;**43**:1379–1400. <https://doi.org/10.1093/eurheartj/ehab832>
13. Lala A, Coca S, Feinman J, Hamo CE, Fiuzat M, Abraham WT, et al. Standardized definitions of changes in kidney function in trials of heart failure: JACC expert panel from the HF-ARC. *J Am Coll Cardiol* 2025;**85**:766–781. <https://doi.org/10.1016/j.jacc.2024.11.041>
14. Kobayashi M, Pitt B, Ferreira JP, Rossignol P, Girerd N, Zannad F. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease. *Eur Heart J* 2025;**46**:2618–2642. <https://doi.org/10.1093/eurheartj/ehaf225>
15. Bozkurt B. The need to stop inappropriate coding for acute kidney injury in heart failure. *JACC Heart Fail* 2022;**10**:692–694. <https://doi.org/10.1016/j.jchf.2022.08.001>
16. Beghini A, Sammartino AM, Papp Z, von Haehling S, Biegus J, Ponikowski P, et al. 2024 update in heart failure. *ESC Heart Fail* 2025;**12**:8–42. <https://doi.org/10.1002/ehf2.14857>
17. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC *Eur J Heart Fail* 2022;**24**:4–131. <https://doi.org/10.1002/ehf.2333>
18. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2022;**79**:e263–e421. <https://doi.org/10.1016/j.jacc.2021.12.012>
19. Ralston SH, Caine N, Richards I, O'Reilly D, Sturrock RD, Capell HA. Screening for proteinuria in a rheumatology clinic: Comparison of dipstick testing, 24 hour urine quantitative protein, and protein/creatinine ratio in random urine samples. *Ann Rheum Dis* 1988;**47**:759–763. <https://doi.org/10.1136/ard.47.9.759>
20. Vissersen FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC Scientific Document Group 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;**42**(34):3227–3337. <https://doi.org/10.1093/eurheartj/ehab484>
21. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018;**39**(33):3021–3104. <https://doi.org/10.1093/eurheartj/ehy339>
22. American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: Standards of care in diabetes-2025. *Diabetes Care* 2025;**48**:S239–S251. <https://doi.org/10.2337/dc25-S011>
23. Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: Known knowns and known unknowns. *Kidney Int* 2024;**105**:684–701. <https://doi.org/10.1016/j.kint.2023.10.016>
24. Sokolski M, Zymliński R, Biegus J, Siwolowski P, Nawrocka-Millward S, Todd J, et al. Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. *Eur J Heart Fail* 2017;**19**:760–767. <https://doi.org/10.1002/ehf.746>
25. Dupont M, Shrestha K, Singh D, Awad A, Kovach C, Scarpino M, et al. Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. *Eur J Heart Fail* 2012;**14**:597–604. <https://doi.org/10.1093/eurjhf/hfs039>
26. Zymliński R, Sierpinski R, Metra M, Cotter G, Sokolski M, Siwolowski P, et al. Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. *ESC Heart Fail* 2020;**7**:3536–3544. <https://doi.org/10.1002/ehf2.13064>
27. Biegus J, Nawrocka-Millward S, Zymliński R, Fudim M, Testani J, Marciniak D, et al. Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. *Int J Cardiol* 2021;**345**:54–60. <https://doi.org/10.1016/j.ijcard.2021.10.149>
28. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *J Am Coll Cardiol* 2009;**53**:589–596. <https://doi.org/10.1016/j.jacc.2008.05.068>
29. Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. *J Lab Clin Med* 1983;**102**:450–458.
30. Biegus J, Zymliński R, Fudim M, Testani J, Sokolski M, Marciniak D, et al. Spot urine sodium in acute heart failure: Differences in prognostic value on admission and discharge. *ESC Heart Fail* 2021;**8**:2597–2602. <https://doi.org/10.1002/ehf2.13372>
31. Honda S, Nagai T, Nishimura K, Nakai M, Honda Y, Nakano H, et al.; NaDEF Investigators. Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. *Int J Cardiol* 2018;**254**:189–194. <https://doi.org/10.1016/j.ijcard.2017.08.053>
32. Mullens W, Verbrugge FH, Nijst P, Tang WHW. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. *Eur Heart J* 2017;**38**:1872–1882. <https://doi.org/10.1093/eurheartj/ehx035>
33. Biegus J, Zymliński R, Testani J, Fudim M, Cox ZL, Guzik M, et al. The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. The role of furosemide urine excretion on diuretic and natriuretic response in acute heart failure. *Eur J Heart Fail* 2023;**25**:1323–1333. <https://doi.org/10.1002/ehf.2852>
34. Kaissling B, Bachmann S, Kriz W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. *Am J Physiol* 1985;**248**:F374–F381. <https://doi.org/10.1152/ajprenal.1985.248.3.F374>
35. Biegus J, Zymliński R, Ponikowski P. Loop diuretics in heart failure: The objective markers to guide the therapy are needed. *ESC Heart Fail* 2024;**11**:1816–1818. <https://doi.org/10.1002/ehf2.14920>
36. Biegus J, Zymliński R, Sokolski M, Todd J, Cotter G, Metra M, et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. *Eur J Heart Fail* 2019;**21**:624–633. <https://doi.org/10.1002/ehf.1428>
37. Vazir A, Kapelios CJ, Agaoglu E, Metra M, Lopatin Y, Seferovic P, et al. Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians. *Eur J Heart Fail* 2023;**25**:1555–1570. <https://doi.org/10.1002/ehf.2985>
38. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;**21**:137–155. <https://doi.org/10.1002/ehf.1369>
39. Verbrugge FH, Martens P, Dauw J, Nijst P, Meekers E, Augusto SN Jr, et al. Natriuretic response to acetazolamide in patients with acute heart failure and volume overload. *J Am Coll Cardiol* 2023;**81**:2013–2024. <https://doi.org/10.1016/j.jacc.2023.03.400>
40. Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Postmus D, Coster JE, et al. Natriuresis-guided diuretic therapy in acute heart failure: A pragmatic randomized trial. *Nat Med* 2023;**29**:2625–2632. <https://doi.org/10.1038/s41591-023-02532-z>
41. Dauw J, Charaya K, Lelonek M, Zegri-Reiriz I, Nasr S, Paredes-Paucar CP, et al. Protocolized natriuresis-guided decongestion improves diuretic response: The multicenter ENACT-HF study. *Circ Heart Fail* 2024;**17**:e011105. <https://doi.org/10.1161/CIRCHEARTFAILURE.123.011105>
42. Guzik M, Iwanek G, Fudim M, Zymliński R, Marciniak D, Ponikowski P, et al. Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure. *Sci Rep* 2024;**14**:1494. <https://doi.org/10.1038/s41598-024-51744-x>
43. Biegus J, Zymliński R, Testani J, Marciniak D, Zdanowicz A, Jankowska EA, et al. Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. *Eur J Heart Fail* 2021;**23**:729–739. <https://doi.org/10.1002/ehf.2053>
44. Iwanek G, Guzik M, Zymliński R, Fudim M, Ponikowski P, Biegus J. Spot urine sodium-to-creatinine ratio surpasses sodium in identifying poor diuretic response in acute heart failure. *ESC Heart Fail* 2024;**11**:3438–3442. <https://doi.org/10.1002/ehf2.14883>
45. Rao VS, Ivey-Miranda JB, Cox ZL, Riello R, Griffin M, Fleming J, et al. Natriuretic equation to predict loop diuretic response in patients with heart failure. *J Am Coll Cardiol* 2021;**77**:695–708. <https://doi.org/10.1016/j.jacc.2020.12.022>
46. Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. *J Card Fail* 2014;**20**:392–399. <https://doi.org/10.1016/j.cardfail.2014.03.006>
47. Ferreira JP, Girerd N, Medeiros PB, Santos M, Carvalho HC, Bettencourt P, et al. Spot urine sodium excretion as prognostic marker in acutely decompensated

- heart failure: The spironolactone effect. *Clin Res Cardiol* 2016;**105**:489–507. <https://doi.org/10.1007/s00392-015-0945-x>
48. Doering A, Jenkins CA, Storrow AB, Lindenfeld J, Fermann GJ, Miller KF, et al. Markers of diuretic resistance in emergency department patients with acute heart failure. *Int J Emerg Med* 2017;**10**:17. <https://doi.org/10.1186/s12245-017-0143-x>
 49. Brinkley DM Jr, Burpee LJ, Chaudhry SP, Smallwood JA, Lindenfeld J, Lakdawala NK, et al. Spot urine sodium as triage for effective diuretic infusion in an ambulatory heart failure unit. *J Card Fail* 2018;**24**:349–354. <https://doi.org/10.1016/j.cardfail.2018.01.009>
 50. Luk A, Groarke JD, Desai AS, Mahmood SS, Gopal DM, Joyce E, et al. First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. *Am Heart J* 2018;**203**:95–100. <https://doi.org/10.1016/j.ahj.2018.01.013>
 51. Collins SP, Jenkins CA, Baughman A, Miller KF, Storrow AB, Han JH, et al. Early urine electrolyte patterns in patients with acute heart failure. *ESC Heart Fail* 2019;**6**:80–88. <https://doi.org/10.1002/ehf2.12368>
 52. Caravaca Pérez P, Nuche J, Morán Fernández L, Lora D, Blázquez-Bermejo Z, López-Azor JC, et al. Potential role of natriuretic response to furosemide stress test during acute heart failure. *Circ Heart Fail* 2021;**14**:e008166. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.008166>
 53. Elias C, Oliveira D, Soares-Carreira M, Amorim M, Araújo JP, Bettencourt P, et al. The ratio of furosemide dosage to urinary sodium concentration predicts mortality in patients with chronic stable heart failure. *Pol Arch Intern Med* 2021;**131**:16083. <https://doi.org/10.20452/pamw.16083>
 54. Damman K, Ter Maaten JM, Coster JE, Krikken JA, van Deursen VM, Krijnen HK, et al. Clinical importance of urinary sodium excretion in acute heart failure. *Eur J Heart Fail* 2020;**22**:1438–1447. <https://doi.org/10.1002/ehf2.1753>
 55. Cobo Marcos M, de la Espriella R, Zegri-Reiriz I, Llacer P, Rubio Gracia J, Comin-Colet J, et al. Early diuretic response and outcome prediction in ambulatory worsening heart failure: Natriuresis versus diuresis. *ESC Heart Fail* 2025;**12**:2460–2466. <https://doi.org/10.1002/ehf2.15275>
 56. Hodson DZ, Griffin M, Mahoney D, Raghavendra P, Ahmad T, Turner J, et al. Natriuretic response is highly variable and associated with 6-month survival: Insights from the ROSE-AHF trial. *JACC Heart Fail* 2019;**7**:383–391. <https://doi.org/10.1016/j.jchf.2019.01.007>
 57. Martens P, Chen HH, Verbrugge FH, Testani JT, Mullens W, Tang WHW. Assessing intrinsic renal sodium avidity in acute heart failure: Implications in predicting and guiding decongestion. *Eur J Heart Fail* 2022;**24**:1978–1987. <https://doi.org/10.1002/ehf2.2662>
 58. Martens P, Dupont M, Verbrugge FH, Damman K, Degryse N, Nijst P, et al. Urinary sodium profiling in chronic heart failure to detect development of acute decompensated heart failure. *JACC Heart Fail* 2019;**7**:404–414. <https://doi.org/10.1016/j.jchf.2019.02.011>
 59. Meekers E, Martens P, Knevels R, Miseur M, Ezzat A, Croset F, et al. Home-based urinary sodium monitoring via point-of-care testing for personalized diuretic titration in heart failure management: The EASY-STOP study. *Eur J Heart Fail* 2025;**27**:950–959. <https://doi.org/10.1002/ehf2.3693>
 60. Kataoka H. Chloride in heart failure syndrome: Its pathophysiologic role and therapeutic implication. *Cardiol Ther* 2021;**10**:407–428. <https://doi.org/10.1007/s40119-021-00238-2>
 61. Kataoka H. Neurohormonal activation and renal chloride avidity in acute heart failure: Clinical evidence supporting the “chloride theory”. *Cardiorenal Med* 2024;**14**:94–104. <https://doi.org/10.1159/000536293>
 62. Nawrocka-Millward S, Biegus J, Fudim M, Guzik M, Iwanek G, Ponikowski P, et al. The role of urine chloride in acute heart failure. *Sci Rep* 2024;**14**:14100. <https://doi.org/10.1038/s41598-024-64747-5>
 63. Xanthopoulos A, Christofidis C, Pantisios C, Magouliotis D, Bourazana A, Leventis I, et al. The prognostic role of spot urinary sodium and chloride in a cohort of hospitalized advanced heart failure patients: A pilot study. *Life (Basel)* 2023;**13**:698. <https://doi.org/10.3390/life13030698>
 64. Guzik M, Zymliński R, Ponikowski P, Biegus J. Urine chloride trajectory and relationship with diuretic response in acute heart failure. *ESC Heart Fail* 2025;**12**:133–141. <https://doi.org/10.1002/ehf2.15054>
 65. Brown RS. Fractional excretion of sodium and urea are useful tools in the evaluation of AKI: Commentary. *Kidney360* 2023;**4**:e731–e3. <https://doi.org/10.34067/KID.0002502022>
 66. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. *J Am Coll Cardiol* 2020;**75**:1178–1195. <https://doi.org/10.1016/j.jacc.2019.12.059>
 67. Watanabe Y, Kubota Y, Nishino T, Tara S, Kato K, Hayashi D, et al. Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure. *ESC Heart Fail* 2024;**11**:2043–2054. <https://doi.org/10.1002/ehf2.14755>
 68. Watanabe Y, Kubota Y, Nishino T, Tara S, Kato K, Hayashi D, et al. Utility of fractional excretion of urea nitrogen in heart failure patients with chronic kidney disease. *ESC Heart Fail* 2023;**10**:1706–1716. <https://doi.org/10.1002/ehf2.14327>
 69. Boorsma EM, Ter Maaten JM, Voors AA, van Veldhuisen DJ. Renal compression in heart failure: The renal tamponade hypothesis. *JACC Heart Fail* 2022;**10**:175–183. <https://doi.org/10.1016/j.jchf.2021.12.005>
 70. Nijst P, Verbrugge FH, Grieten L, Dupont M, Steels P, Tang WHW, et al. The pathophysiological role of interstitial sodium in heart failure. *J Am Coll Cardiol* 2015;**65**:378–388. <https://doi.org/10.1016/j.jacc.2014.11.025>
 71. Cleland JG, Dargie HJ, Robertson I, Robertson JI, East BW. Total body electrolyte composition in patients with heart failure: A comparison with normal subjects and patients with untreated hypertension. *Br Heart J* 1987;**58**:230–238. <https://doi.org/10.1136/hrt.58.3.230>
 72. Claudel SE, Verma A. Albuminuria in cardiovascular, kidney, and metabolic disorders: A state-of-the-art review. *Circulation* 2025;**151**:716–732. <https://doi.org/10.1161/CIRCULATIONAHA.124.071079>
 73. Österman J, Al-Sodany E, Haugen Löfman I, Barany P, Evans M. Heart failure: The grim reaper of the cardio-renal-metabolic triad. *ESC Heart Fail* 2024;**11**:2334–2343. <https://doi.org/10.1002/ehf2.14810>
 74. Khan MS, Shahid I, Anker SD, Fonarow GC, Fudim M, Hall ME, et al. Albuminuria and heart failure: JACC state-of-the-art review. *J Am Coll Cardiol* 2023;**81**:270–282. <https://doi.org/10.1016/j.jacc.2022.10.028>
 75. Otaki Y, Watanabe T, Shimizu M, Tachibana S, Sato J, Kobayashi Y, et al. Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease. *ESC Heart Fail* 2023;**10**:2458–2468. <https://doi.org/10.1002/ehf2.14378>
 76. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int* 2024;**105**:S117–s314. <https://doi.org/10.1016/j.kint.2023.10.018>
 77. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The Framingham Heart Study. *Circulation* 2005;**112**:969–975. <https://doi.org/10.1161/CIRCULATIONAHA.105.538132>
 78. Verma A, Schmidt IM, Claudel S, Palsson R, Waikar SS, Srivastava A. Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria: A cohort study. *Ann Intern Med* 2024;**177**:467–475. <https://doi.org/10.7326/M23-2814>
 79. Claudel SE, Waikar SS, Schmidt IM, Vasan RS, Verma A. The relationship between low levels of albuminuria and mortality among adults without major cardiovascular risk factors. *Eur J Prev Cardiol* 2024;**31**:2046–2055. <https://doi.org/10.1093/eurjpc/zwae189>
 80. de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhamhani V, Kizer JR, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. *JAMA Cardiol* 2018;**3**:215–224. <https://doi.org/10.1001/jamacardio.2017.4987>
 81. Bahrami H, Bluemke DA, Kronmal R, Bertoni AG, Lloyd-Jones DM, Shahar E, et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: The MESA (Multi-Ethnic Study of Atherosclerosis) study. *J Am Coll Cardiol* 2008;**51**:1775–1783. <https://doi.org/10.1016/j.jacc.2007.12.048>
 82. Blecker S, Matsushita K, Köttgen A, Loehr LR, Bertoni AG, Boulware LE, et al. High-normal albuminuria and risk of heart failure in the community. *Am J Kidney Dis* 2011;**58**:47–55. <https://doi.org/10.1053/j.ajkd.2011.02.391>
 83. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation* 2004;**110**:921–927. <https://doi.org/10.1161/01.CIR.0000139860.33974.28>
 84. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al.; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *J Am Soc Nephrol* 2009;**20**:1813–1821. <https://doi.org/10.1681/ASN.2008121270>
 85. Nayor M, Larson MG, Wang N, Santhanakrishnan R, Lee DS, Tsao CW, et al. The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction. *Eur J Heart Fail* 2017;**19**:615–623. <https://doi.org/10.1002/ehf2.778>
 86. Vaduganathan M, Pareek M, Kristensen AMD, Biering-Sørensen T, Byrne C, Almarzooq Z, et al. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: A SPRINT substudy. *Eur J Heart Fail* 2021;**23**:384–392. <https://doi.org/10.1002/ehf2.1971>
 87. Filippos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, et al. Finerenone and heart failure outcomes by kidney function/albuminuria in chronic kidney disease and diabetes. *JACC Heart Fail* 2022;**10**:860–870. <https://doi.org/10.1016/j.jchf.2022.07.013>

88. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001;**286**:421–426. <https://doi.org/10.1001/jama.286.4.421>
89. Velagaleti RS, Gona P, Larson MG, Wang TJ, Levy D, Benjamin EJ, et al. Multi-marker approach for the prediction of heart failure incidence in the community. *Circulation* 2010;**122**:1700–1706. <https://doi.org/10.1161/CIRCULATIONAHA.109.929661>
90. Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular–kidney–metabolic health: A scientific statement from the American Heart Association. *Circulation* 2023;**148**:1982–2004. <https://doi.org/10.1161/CIR.0000000000001191>
91. Masson S, Latini R, Milani V, Moretti L, Rossi MG, Carbonieri E, et al.; GISSI-HF Investigators. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: Data from the GISSI-Heart Failure trial. *Circ Heart Fail* 2010;**3**:65–72. <https://doi.org/10.1161/CIRCHEARTFAILURE.109.881805>
92. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al.; CHARM Investigators and Committees. Albuminuria in chronic heart failure: Prevalence and prognostic importance. *Lancet* 2009;**374**:543–550. [https://doi.org/10.1016/S0140-6736\(09\)61378-7](https://doi.org/10.1016/S0140-6736(09)61378-7)
93. Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O'Meara E, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. *Circ Heart Fail* 2018;**11**:e005288. <https://doi.org/10.1161/CIRCHEARTFAILURE.118.005288>
94. Miura M, Shiba N, Nochioka K, Takada T, Takahashi J, Kohno H, et al.; on behalf of the CHART-2 Investigators. Urinary albumin excretion in heart failure with preserved ejection fraction: An interim analysis of the CHART 2 study. *Eur J Heart Fail* 2012;**14**:367–376. <https://doi.org/10.1093/eurjhf/hfs001>
95. Shuvy M, Zwas DR, Lotan C, Keren A, Gotsman I. Albuminuria: Associated with heart failure severity and impaired clinical outcomes. *Can J Cardiol* 2020;**36**:527–534. <https://doi.org/10.1016/j.cjca.2019.09.001>
96. Katz DH, Burns JA, Aguilar FG, Beussink L, Shah SJ. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. *JACC Heart Fail* 2014;**2**:586–596. <https://doi.org/10.1016/j.jchf.2014.05.016>
97. Wegria R, Capeci NE, Blumenthal MR, Kornfeld P, Hays DR, Elias RA, et al. The pathogenesis of proteinuria in the acutely congested kidney. *J Clin Invest* 1955;**34**:737–743. <https://doi.org/10.1172/JCI103127>
98. Latham W, Roof BS, Nickel JF, Bradley SE. Urinary protein excretion and renal hemodynamic adjustments during orthostasis in patients with acute and chronic renal diseases. *J Clin Invest* 1954;**33**:1457–1465. <https://doi.org/10.1172/JCI103024>
99. Llàcer P, Crosset F, de la Espriella R, Torres E, Campos J, Garcia-Melero M, et al. Trajectory of urine albumin-creatinine ratio in patients with acute heart failure. *Cardiorenal Med* 2024;**14**:74–80. <https://doi.org/10.1159/000536222>
100. Koyama S, Sato Y, Tanada Y, Fujiwara H, Takatsu Y. Early evolution and correlates of urine albumin excretion in patients presenting with acutely decompensated heart failure. *Circ Heart Fail* 2013;**6**:227–232. <https://doi.org/10.1161/CIRCHEARTFAILURE.112.000152>
101. Matsumoto Y, Orihara Y, Asakura M, Min KD, Okuhara Y, Azuma K, et al. Urine albumin-to-creatinine ratio on admission predicts early rehospitalization in patients with acutely decompensated heart failure. *Heart Vessels* 2022;**37**:1184–1194. <https://doi.org/10.1007/s00380-022-02025-y>
102. Boorsma EM, Ter Maaten JM, Damman K, van Essen BJ, Zannad F, van Veldhuisen DJ, et al. Albuminuria as a marker of systemic congestion in patients with heart failure. *Eur Heart J* 2023;**44**:368–380. <https://doi.org/10.1093/eurheartj/ehac528>
103. Ioannou A, Rauf MU, Patel RK, Razvi Y, Porcari A, Martinez-Naharro A, et al. Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance. *Eur J Heart Fail* 2024;**26**:65–73. <https://doi.org/10.1002/ehfj.3094>
104. Kula AJ, Hanberg JS, Wilson FP, Brisco MA, Bellumkonda L, Jacoby D, et al. Influence of titration of neurohormonal antagonists and blood pressure reduction on renal function and decongestion in decompensated heart failure. *Circ Heart Fail* 2016;**9**:e002333. <https://doi.org/10.1161/CIRCHEARTFAILURE.115.002333>
105. Biegus J, Cotter G, Metra M, Ponikowski P. Decongestion in acute heart failure: Is it time to change diuretic-centred paradigm? *Eur J Heart Fail* 2024;**26**:2094–2106. <https://doi.org/10.1002/ehfj.3423>
106. Biegus J, Fudim M, Salah HM, Heerspink HJL, Voors AA, Ponikowski P. Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies. *Eur J Heart Fail* 2023;**25**:1526–1536. <https://doi.org/10.1002/ehfj.2967>
107. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial. *Lancet* 2022;**400**:1938–1952. [https://doi.org/10.1016/S0140-6736\(22\)02076-1](https://doi.org/10.1016/S0140-6736(22)02076-1)
108. Biegus J, Mebazaa A, Davison B, Cotter G, Edwards C, Celutkienė J, et al. Effects of rapid up-titration of neurohormonal blockade on effective, sustainable decongestion and outcomes in STRONG-HF. *J Am Coll Cardiol* 2024;**84**:323–336. <https://doi.org/10.1016/j.jacc.2024.04.055>
109. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 2020;**383**(22):2219–2229. <https://doi.org/10.1056/NEJMoa2025845>
110. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and in type 2 diabetes. *N Engl J Med* 2021;**385**(24):2252–2263. <https://doi.org/10.1056/NEJMoa2110956>
111. Perkovic V, Jardine MJ, Neal B, Bompaint S, Heerspink HJL, Charytan DM, et al.; CREDESCENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;**380**(24):2295–2306. <https://doi.org/10.1056/NEJMoa1811744>
112. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 2020;**383**(15):1436–1446. <https://doi.org/10.1056/NEJMoa2024816>
113. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al.; EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. *N Engl J Med* 2023;**388**(2):117–127. <https://doi.org/10.1056/NEJMoa2204233>
114. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;**345**(12):861–869. <https://doi.org/10.1056/NEJMoa011161>
115. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med* 2012;**367**:2204–2213. <https://doi.org/10.1056/NEJMoa1208799>
116. Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al.; Chronic Kidney Disease Epidemiology Collaboration. Change in albuminuria as a surrogate endpoint for progression of kidney disease: A meta-analysis of treatment effects in randomised clinical trials. *Lancet Diabetes Endocrinol* 2019;**7**(2):128–139. [https://doi.org/10.1016/S2213-8587\(18\)30314-0](https://doi.org/10.1016/S2213-8587(18)30314-0)
117. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. *Am J Kidney Dis* 2020;**75**:84–104. <https://doi.org/10.1053/j.ajkd.2019.06.009>
118. Abassi ZA, Kelly G, Golomb E, Klein H, Keiser HR. Losartan improves the natriuretic response to ANF in rats with high-output heart failure. *J Pharmacol Exp Ther* 1994;**268**:224–230. [https://doi.org/10.1016/S0022-3565\(25\)38470-3](https://doi.org/10.1016/S0022-3565(25)38470-3)
119. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waerber B, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. *Hypertension* 1993;**22**:339–347. <https://doi.org/10.1161/01.hyp.22.3.339>
120. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *N Engl J Med* 2011;**364**(10):907–917. <https://doi.org/10.1056/NEJMoa1007994>
121. Ruggenenti P, Fassio A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. *N Engl J Med* 2004;**351**(19):1941–1951. <https://doi.org/10.1056/NEJMoa042167>
122. Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. *Diabetes Obes Metab* 2016;**18**:169–177. <https://doi.org/10.1111/dom.12600>
123. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. *Lancet* 2003;**362**:759–766. [https://doi.org/10.1016/S0140-6736\(03\)14282-1](https://doi.org/10.1016/S0140-6736(03)14282-1)
124. Capes SE, Gerstein HC, Negassa A, Yusuf S. Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. *Diabetes Care* 2000;**23**:377–380. <https://doi.org/10.2337/diacare.23.3.377>
125. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions

- and congestive heart failure *N Engl J Med* 1991;**325**(5):293–302. <https://doi.org/10.1056/NEJM199108013250501>
126. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: The PARADIGM-HF trial. *Eur J Heart Fail* 2019;**21**:337–341. <https://doi.org/10.1002/ehjhf.1402>
 127. Mebazaa A, Davison BA, Biegus J, Edwards C, Murtagh G, Varounis C, et al. Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATORIUM-HF study. *Eur J Heart Fail* 2024;**26**:1507–1517. <https://doi.org/10.1002/ehjhf.3265>
 128. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al.; PIONEER-HF Investigators. Angiotensin-nepriylsin inhibition in acute decompensated heart failure. *N Engl J Med* 2019;**380**:539–548. <https://doi.org/10.1056/NEJMoa1812851>
 129. Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al.; PARAGLIDE-HF Investigators. Angiotensin-nepriylsin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. *J Am Coll Cardiol* 2023;**82**(1):1–12. <https://doi.org/10.1016/j.jacc.2023.04.019>
 130. Tanaka A, Kida K, Matsue Y, Imai T, Suwa S, Taguchi I, et al. In-hospital initiation of angiotensin receptor-nepriylsin inhibition in acute heart failure: The PREMIER trial. *Eur Heart J* 2024;**45**:4482–4493. <https://doi.org/10.1093/eurheartj/ehae561>
 131. Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, et al.; UK HARP-III Collaborative Group. Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. *Circulation* 2018;**138**:1505–1514. <https://doi.org/10.1161/CIRCULATIONAHA.118.034818>
 132. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-nepriylsin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;**371**:993–1004. <https://doi.org/10.1056/NEJMoa1409077>
 133. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-nepriylsin inhibition in heart failure. *JACC Heart Fail* 2018;**6**:489–498. <https://doi.org/10.1016/j.jchf.2018.02.004>
 134. Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, et al. Renal effects of the angiotensin receptor nepriylsin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. *Eur J Heart Fail* 2015;**17**:510–517. <https://doi.org/10.1002/ehjhf.232>
 135. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al.; Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection fracTion (PARAMOUNT) Investigators. The angiotensin receptor nepriylsin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. *Lancet* 2012;**380**:1387–1395. [https://doi.org/10.1016/S0140-6736\(12\)61227-6](https://doi.org/10.1016/S0140-6736(12)61227-6)
 136. Pieske B, Wachter R, Shah SJ, Baldrige A, Szeceody P, Ibram G, et al.; PARALLAX Investigators and Committee members. Effect of sacubitril/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial. *JAMA* 2021;**326**(19):1919–1929. <https://doi.org/10.1001/jama.2021.18463>
 137. Packer M. Pitfalls in using estimated glomerular filtration rate slope as a surrogate for the effect of drugs on the risk of serious adverse renal outcomes in clinical trials of patients with heart failure. *Circ Heart Fail* 2021;**14**:e008537. <https://doi.org/10.1161/CIRCHEARTFAILURE.121.008537>
 138. Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-nepriylsin inhibition and renal outcomes in heart failure with preserved ejection fraction. *Circulation* 2020;**142**:1236–1245. <https://doi.org/10.1161/CIRCULATIONAHA.120.047643>
 139. Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S. Nepriylsin inhibitors in heart failure: The science, mechanism of action, clinical studies, and unanswered questions. *JACC Basic Transl Sci* 2023;**8**:88–105. <https://doi.org/10.1016/j.jacbts.2022.05.010>
 140. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, et al.; GEMINI Investigators. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. *Hypertension* 2005;**46**:1309–1315. <https://doi.org/10.1161/01.HYP.0000190585.54734.48>
 141. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. *Eur J Intern Med* 2014;**25**:67–72. <https://doi.org/10.1016/j.ejim.2013.08.711>
 142. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. *J Cardiovasc Pharmacol* 2014;**64**:69–78. <https://doi.org/10.1097/FJC.000000000000091>
 143. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al.; National Heart Lung and Blood Institute Heart Failure Clinical Research Network. Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial. *JAMA Cardiol* 2017;**2**:950–958. <https://doi.org/10.1001/jamacardio.2017.2198>
 144. Kobayashi M, Ferreira JP, Matsue Y, Chikamori T, Ito S, Asakura M, et al. Effect of eplerenone on clinical stability of Japanese patients with acute heart failure. *Int J Cardiol* 2023;**374**:73–78. <https://doi.org/10.1016/j.ijcard.2022.12.045>
 145. Asakura M, Ito S, Yamada T, Saito Y, Kimura K, Yamashina A, et al. Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): A multicentre, randomized, double-blind, placebo-controlled trial. *Eur Heart J Cardiovasc Pharmacother* 2022;**8**:108–117. <https://doi.org/10.1093/ehjcvp/pvaa132>
 146. Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. *Cochrane Database Syst Rev* 2020;**10**:CD007004. <https://doi.org/10.1002/14651858.CD007004.pub4>
 147. Oiwa A, Hiwatashi D, Takeda T, Miyamoto T, Kawata I, Koinuma M, et al. Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes. *J Clin Endocrinol Metab* 2023;**108**:2203–2210. <https://doi.org/10.1210/clinem/dgad144>
 148. Brandt-Jacobsen NH, Johansen ML, Rasmussen J, Forman JL, Holm MR, Faber J, et al. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial. *Diabetes Metab* 2021;**47**:101190. <https://doi.org/10.1016/j.diabet.2020.08.005>
 149. Ferreira JP, Oliveira AC, Vasques-Novoa F, Leite AR, Mendonça L, Zannad F, et al. Mineralocorticoid receptor antagonist combined with SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: A meta-analysis of randomized trials. *Am J Nephrol* 2025;**56**:236–242. <https://doi.org/10.1159/000541686>
 150. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al.; Mineralocorticoid Receptor Antagonist Tolerability Study—Diabetic Nephropathy (ARTS-DN) Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. *JAMA* 2015;**314**(9):884–894. <https://doi.org/10.1001/jama.2015.10081>
 151. Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, et al.; FIDELIO-DKD and FIGARO-DKD Investigators. Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: A mediation analysis. *Ann Intern Med* 2023;**176**(12):1606–1616. <https://doi.org/10.7326/M23-1023>
 152. Pitt B, Kober L, Ponikowski P, Gheorghiadu M, Filipatos G, Krum H, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. *Eur Heart J* 2013;**34**:2453–2463. <https://doi.org/10.1093/eurheartj/ehs187>
 153. Mc Causland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Finerenone and kidney outcomes in patients with heart failure: The FINEARTS-HF trial. *J Am Coll Cardiol* 2025;**85**:159–168. <https://doi.org/10.1016/j.jacc.2024.10.091>
 154. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al.; FINEARTS-HF Committees and Investigators. Finerenone in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 2024;**391**(16):1475–1485. <https://doi.org/10.1056/NEJMoa2407107>
 155. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. *Circulation* 2015;**131**:34–42. <https://doi.org/10.1161/CIRCULATIONAHA.114.013255>
 156. Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al.; CONFIDENCE Investigators. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. *N Engl J Med* 2025;**393**:533–543. <https://doi.org/10.1056/NEJMoa2410659>
 157. Ferreira JP, Vasques-Novoa F, Saraiva F, Oliveira AC, Almeida J, Batista AB, et al. SGLT2 inhibitor with and without ALDosterone Antagonist for heart failure with preserved ejection fraction: Design paper. *ESC Heart Fail* 2025;**12**:3134–3144. <https://doi.org/10.1002/ehf2.15294>
 158. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure: Diuretic and cardiorenal effects. *Circulation* 2020;**142**:1028–1039. <https://doi.org/10.1161/CIRCULATIONAHA.120.045691>
 159. Rao VS, Ivey-Miranda JB, Cox ZL, Moreno-Villagomez J, Maulion C, Bel-lumkonda L, et al. Empagliflozin in heart failure: Regional nephron sodium handling effects. *J Am Soc Nephrol* 2024;**35**:189–201. <https://doi.org/10.1681/ASN.0000000000000269>

160. Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30%-50% of renal glucose reabsorption in humans? *Diabetes* 2012;**61**:2199–2204. <https://doi.org/10.2337/db12-0052>
161. Mullens W, Martens P. Empagliflozin and renal sodium handling: An intriguing smart osmotic diuretic. *Eur J Heart Fail* 2021;**23**:79–82. <https://doi.org/10.1002/ehf.2086>
162. Boorsma EM, Beusekamp JC, Ter Maaten JM, Figarska SM, Danser AHJ, van Veldhuisen DJ, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. *Eur J Heart Fail* 2021;**23**:68–78. <https://doi.org/10.1002/ehf.2066>
163. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). *Eur J Heart Fail* 2020;**22**:713–722. <https://doi.org/10.1002/ehf.1713>
164. Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). *Circulation* 2022;**146**:289–298. <https://doi.org/10.1161/CIRCULATIONAHA.122.059038>
165. Cox ZL, Collins SP, Hernandez GA, McRae AT 3rd, Davidson BT, Adams K, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. *J Am Coll Cardiol* 2024;**83**:1295–1306. <https://doi.org/10.1016/j.jacc.2024.02.009>
166. Tamaki S, Yamada T, Watanabe T, Morita T, Furukawa Y, Kawasaki M, et al. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: A prospective randomized controlled study. *Circ Heart Fail* 2021;**14**:e007048. <https://doi.org/10.1161/CIRCHEARTFAILURE.120.007048>
167. Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. *Eur Heart J* 2023;**44**:2966–2977. <https://doi.org/10.1093/eurheartj/ehad341>
168. Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: The RECEDE-CHF trial. *Circulation* 2020;**142**:1713–1724. <https://doi.org/10.1161/CIRCULATIONAHA.120.048739>
169. Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, et al. The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: Results from a placebo-controlled randomised trial. *Clin Res Cardiol* 2023;**112**:134–144. <https://doi.org/10.1007/s00392-022-02119-7>
170. Marton A, Saffari SE, Rauh M, Sun RN, Nagel AM, Linz P, et al. Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure. *J Am Coll Cardiol* 2024;**83**:1386–1398. <https://doi.org/10.1016/j.jacc.2024.02.020>
171. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. *Nat Med* 2022;**28**:568–574. <https://doi.org/10.1038/s41591-021-01659-1>
172. Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial. *Eur Heart J* 2023;**44**:41–50. <https://doi.org/10.1093/eurheartj/ehac530>
173. Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, Kuder JF, Desai AS, Inzucchi SE, McMurray J, O'Meara E, Verma S, Bělohávek J, Drozdž J, Merkely B, Ogunniyi MO, Dnasran T, Izzo JL, Sarman B, McGinty J, Ramanathan K, Mulkay AJ, Przybylski A, Ruff CT, O'Donoghue ML, Murphy SA, Sabatine MS, Wiviott SD, DAPA ACT HF-TIMI 68 Trial Committees and Investigators. Dapagliflozin in patients hospitalized for heart failure: Primary results of the DAPA ACT HF-TIMI 68 randomized clinical trial and meta-analysis of sodium-glucose cotransporter-2 inhibitors in patients hospitalized for heart failure. *Circulation* 2025;**152**:1411–1422. <https://doi.org/10.1161/CIRCULATIONAHA.125.076575>
174. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. *Lancet* 2019;**393**:31–39. [https://doi.org/10.1016/S0140-6736\(18\)32590-X](https://doi.org/10.1016/S0140-6736(18)32590-X)
175. Jongs N, Greene T, Chertow GM, McMurray JVV, Langkilde AM, Correa-Rotter R, et al. DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial. *Lancet Diabetes Endocrinol* 2021;**9**:755–766. [https://doi.org/10.1016/S2213-8587\(21\)00243-6](https://doi.org/10.1016/S2213-8587(21)00243-6)
176. Petrykiv S, Sjöström CD, Greasley PJ, Xu J, Persson F, Heerspink HJL. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. *Clin J Am Soc Nephrol* 2017;**12**:751–759. <https://doi.org/10.2215/CJN.10180916>
177. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med* 2016;**375**(4):323–334. <https://doi.org/10.1056/NEJMoa1515920>
178. Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol* 2017;**5**:610–621. [https://doi.org/10.1016/S2213-8587\(17\)30182-1](https://doi.org/10.1016/S2213-8587(17)30182-1)
179. Cowie MR, Fisher M. SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control. *Nat Rev Cardiol* 2020;**17**:761–772. <https://doi.org/10.1038/s41569-020-0406-8>
180. Ferreira JP, Zannad F, Butler J, Filippatos G, Pocock SJ, Brueckmann M, et al. Association of empagliflozin treatment with albuminuria levels in patients with heart failure: A secondary analysis of EMPEROR-Pooled. *JAMA Cardiol* 2022;**7**:1148–1159. <https://doi.org/10.1001/jamacardio.2022.2924>
181. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;**383**(15):1413–1424. <https://doi.org/10.1056/NEJMoa2022190>
182. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 2021;**385**(16):1451–1461. <https://doi.org/10.1056/NEJMoa2107038>
183. He L, Wong CK, Cheung KK, Yau HC, Fu A, Zhao HL, et al. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. *J Diabetes Investig* 2013;**4**:382–392. <https://doi.org/10.1111/jdi.12063>
184. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. *Diabetologia* 2011;**54**:965–978. <https://doi.org/10.1007/s00125-010-2028-x>
185. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;**375**:311–322. <https://doi.org/10.1056/NEJMoa1603827>
186. Marso SP, Bain SC, Consoi A, Eliaschewitz FG, Jódar E, Leiter LA, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 2016;**375**(19):1834–1844. <https://doi.org/10.1056/NEJMoa1607141>
187. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. *N Engl J Med* 2023;**389**(24):2221–2232. <https://doi.org/10.1056/NEJMoa2307563>
188. Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. *Nat Med* 2024;**30**:2058–2066. <https://doi.org/10.1038/s41591-024-03015-5>
189. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 2024;**391**(2):109–121. <https://doi.org/10.1056/NEJMoa2403347>
190. Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: Pooled analysis of SUSTAIN 6 and LEADER. *Circulation* 2022;**145**:575–585. <https://doi.org/10.1161/CIRCULATIONAHA.121.055459>
191. Marso SP, Baeres FMM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. *J Am Coll Cardiol* 2020;**75**:1128–1141. <https://doi.org/10.1016/j.jacc.2019.12.063>
192. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al.; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med* 2025;**392**(5):427–437. <https://doi.org/10.1056/NEJMoa2410027>
193. Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: A secondary analysis of the SUMMIT trial. *Nat Med* 2025;**31**:544–551. <https://doi.org/10.1038/s41591-024-03374-z>
194. ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure – pathophysiology, evaluation, and therapy. *Nat Rev Cardiol* 2015;**12**:184–192. <https://doi.org/10.1038/nrcardio.2014.215>

195. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al.; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med* 2011;**364**:797–805. <https://doi.org/10.1056/NEJMoa1005419>
196. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. *J Am Coll Cardiol* 2010;**56**:1527–1534. <https://doi.org/10.1016/j.jacc.2010.06.034>
197. Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Martel M, Conde-Martel A, et al.; CLOROTIC trial investigators. Combining loop with thiazide diuretics for decompensated heart failure: The CLOROTIC trial. *Eur Heart J* 2023;**44**(5):411–421. <https://doi.org/10.1093/eurheartj/ehac689>
198. Morales E, Caro J, Gutierrez E, Sevillano A, Auñón P, Fernandez C, et al. Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease. *Kidney Int* 2015;**88**:1434–1441. <https://doi.org/10.1038/ki.2015.249>
199. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. *J Am Soc Nephrol* 2008;**19**:999–1007. <https://doi.org/10.1681/ASN.2007060693>
200. Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, et al.; Holland Nephrology Study (HONEST) Group. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial. *Lancet Diabetes Endocrinol* 2014;**2**:385–395. [https://doi.org/10.1016/S2213-8587\(14\)70030-0](https://doi.org/10.1016/S2213-8587(14)70030-0)
201. Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. *N Engl J Med* 2021;**385**:2507–2519. <https://doi.org/10.1056/NEJMoa2110730>
202. Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. *Eur J Heart Fail* 2019;**21**:1415–1422. <https://doi.org/10.1002/ehf.1478>
203. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al.; ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. *N Engl J Med* 2022;**387**:1185–1195. <https://doi.org/10.1056/NEJMoa2203094>
204. Konstam MA, Gheorghide M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. *JAMA* 2007;**297**(12):1319–1331. <https://doi.org/10.1001/jama.297.12.1319>
205. Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fuzat M, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. *J Am Coll Cardiol* 2017;**69**:1399–1406. <https://doi.org/10.1016/j.jacc.2016.09.004>
206. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial. *J Am Coll Cardiol* 2008;**52**:1540–1545. <https://doi.org/10.1016/j.jacc.2008.08.013>
207. Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, et al. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: Results from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure). *J Am Coll Cardiol* 2013;**62**:1177–1183. <https://doi.org/10.1016/j.jacc.2013.04.073>
208. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. *N Engl J Med* 2011;**365**:32–43. <https://doi.org/10.1056/NEJMoa1100171>
209. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al.; NHLBI Heart Failure Clinical Research Network. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE Acute Heart Failure randomized trial. *JAMA* 2013;**310**:2533–2543. <https://doi.org/10.1001/jama.2013.282190>
210. Honda S, Nagai T, Honda Y, Nakano H, Kawabata T, Maeda H, et al. Effect of low-dose administration of carperitide for acute heart failure: The LASCAR-AHF trial. *Eur Heart J Acute Cardiovasc Care* 2025;**14**:83–92. <https://doi.org/10.1093/ehjacc/zaee140>
211. Kazory A. Combination diuretic therapy to counter renal sodium avidity in acute heart failure: Trials and tribulations. *Clin J Am Soc Nephrol* 2023;**18**:1372–1381. <https://doi.org/10.2215/CJN.000000000000188>
212. Chung ES, O'Brien TM, Menon S, Bartone C, Mazur WW, Kereiakes DJ. A pilot study of target weight guided treatment in acute heart failure using ultrafiltration or usual care: Effect on sodium removal. *Korean Circ J* 2014;**44**:156–161. <https://doi.org/10.4070/kcj.2014.44.3.156>
213. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. *J Am Coll Cardiol* 2012;**59**:2145–2153. <https://doi.org/10.1016/j.jacc.2011.10.910>
214. Costanzo MR, Negoianu D, Jaski BE, Bart BA, Heywood JT, Anand IS, et al. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. *JACC Heart Fail* 2016;**4**:95–105. <https://doi.org/10.1016/j.jchf.2015.08.005>
215. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al.; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. *J Am Coll Cardiol* 2007;**49**:675–683. <https://doi.org/10.1016/j.jacc.2006.07.073>
216. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, et al. Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Testing Consortium. *Nat Biotechnol* 2010;**28**:455–462. <https://doi.org/10.1038/nbt.1625>
217. Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, et al. Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. *J Am Coll Cardiol* 2018;**72**:1081–1090. <https://doi.org/10.1016/j.jacc.2018.06.050>
218. Becher PM, Lund LH, Coats AJS, Savarese G. An update on global epidemiology in heart failure. *Eur Heart J* 2022;**43**:3005–3007. <https://doi.org/10.1093/eurheartj/ehac248>
219. Streng KW, Hillege HL, Ter Maaten JM, van Veldhuisen DJ, Dickstein K, Samani NJ, et al. Urinary marker profiles in heart failure with reduced versus preserved ejection fraction. *J Cardiovasc Transl Res* 2024;**17**:3–12. <https://doi.org/10.1007/s12265-023-10356-y>
220. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. *J Am Coll Cardiol* 2023;**81**:1810–1834. <https://doi.org/10.1016/j.jacc.2023.01.049>
221. Baumhove L, Tromp J, Figarska S, van Essen BJ, Anker SD, Dickstein K, et al. Heart failure with normal LVEF in BIostat-CHF. *Int J Cardiol* 2022;**364**:85–90. <https://doi.org/10.1016/j.ijcard.2022.05.054>
222. Settergren C, Benson L, Shahim A, Dahlström U, Thorvaldsen T, Savarese G, et al. Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry. *Eur J Heart Fail* 2024;**26**:1150–1159. <https://doi.org/10.1002/ehf.3230>
223. Shin JI, Chang AR, Grams ME, Coresh J, Ballew SH, Surapaneni A, et al.; CKD Prognosis Consortium. Albuminuria testing in hypertension and diabetes: An individual-participant data meta-analysis in a global consortium. *Hypertension* 2021;**78**(4):1042–1052. <https://doi.org/10.1161/HYPERTENSIONAHA.121.17323>
224. Tonelli M, Tiv S, Anand S, Mohan D, Garcia Garcia G, Gutiérrez Padilla JA, et al. Diagnostic yield of population-based screening for chronic kidney disease in low-income, middle-income, and high-income countries. *JAMA Netw Open* 2021;**4**:e2127396. <https://doi.org/10.1001/jamanetworkopen.2021.27396>
225. Szczech LA, Stewart RC, Su HL, DeLoskey RJ, Astor BC, Fox CH, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: The ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). *PLoS One* 2014;**9**:e110535. <https://doi.org/10.1371/journal.pone.0110535>
226. Cox ZL, Siddiqi HK, Stevenson LW, Bales B, Han JH, Hart K, et al. Randomized controlled trial of urine chemistry guided acute heart failure treatment (ESCALATE): Rationale and design. *Am Heart J* 2023;**265**:121–131. <https://doi.org/10.1016/j.ahj.2023.07.014>
227. Vanhentenrijk S, Verbeeck J, Kalpakos T, Vandoren V, Braeckveldt L, L'Hoyes W, et al. Rationale and design of the DECONGEST (Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment) study. *J Card Fail* 2025;**31**:651–660. <https://doi.org/10.1016/j.cardfail.2024.08.044>
228. Meekers E, Martens P, Dauw J, Gruwez H, Dhont S, Nijst P, et al. Nurse-led diuretic titration via a point-of-care urinary sodium sensor in patients with acute decompensated heart failure (EASY-HF): A single-centre, randomized, open-label study. *Eur J Heart Fail* 2024;**26**:2129–2139. <https://doi.org/10.1002/ehf.3429>
229. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al.; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. *JAMA* 2009;**301**(4):383–392. <https://doi.org/10.1001/jama.2009.2>
230. Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). *Circulation* 2018;**137**:1671–1683. <https://doi.org/10.1161/CIRCULATIONAHA.117.029882>